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Bladder cancer is the fourth most common malignant tumour after prostate, lung, 
and colorectal cancer in men and the fifth most common cancer in women in the 
United States. Bladder cancer patients who exhibit high expression of autocrine 
growth factor receptors have significantly lower survival rates. Among all bladder 
cancer patients, those with metastatic bladder cancer had the highest levels of 
HGF in serum and tissue. It has also been suggested that the serum level of HGF 
could be used as a predictor of bladder cancer progression and patient survival. 
Therefore, we are interested to investigate the impact of HGF/c-MET in bladder 
cancer progression. Bladder carcinoma progressed by invading the different layers 
of the bladder wall and one of the causal factors for cell migration and invasion is 
Epithelial Mesenchymal Transition (EMT). Using HGF as an inducer to study 
bladder cancer progression via EMT in vitro could aid the understanding of the 
molecular mechanism behind tumour progression. This study should contribute to 
unravel the stepwise activation and possible cross-talks between signalling 
pathways critical for acquiring the mesenchymal phenotype which provide cells 
the ability to migrate and invade into the bladder wall as well as to metastasize.  
In this study, we have focused on a bladder carcinoma cell line model system to 
unravel mechanisms driving invasive migration. Firstly, we analysed the 
expression profiling at different times during the execution of the EMT 
programme stimulated by hepatocyte growth factor (HGF). We identified the 
significantly differential expressed genes at the different time-points post HGF 
stimulation and performed a pathway analysis. Distinct pathways activated at 
viii 
 
different time-points include MAPK, ERBB, TGF-β and focal adhesion pathways. 
Secondly, we utilised small molecular weight kinase inhibitors to interfere with 
downstream signalling systems to c-Met (HGFR) and identified inhibitors that 
target c-Met, MEK, PI3K and TGFRβ. The shortlisted inhibitors were able to 
block EMT and transwell migration. Next, we tested the potential of a TGFβRI 
inhibitor on an orthotopic bladder mouse model and shown that carcinoma 
bladder wall invasion was delayed in inhibitor-treated mice. Our studies provide 
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Chapter1: Introduction  
 
Epithelial Mesenchymal Transition 
Epithelial Mesenchymal Transition (EMT) is a fundamental mechanism that 
drives the transdifferentiation of epithelial cells into mesenchymal cells, 
accompanied by the loss of apico-basal polarity of epithelial cells and the 
acquisition of fibroblastic-like morphology. EMT is an essential process for the 
body plan formation and the associated morphological and biochemical changes 
of most metazoans during gastrulation. The primitive ectoderm undergoes a major 
reorganisation in order to establish the formation of two layers in the diploblasts 
and three layers in triploblasts, which is achieved via the plasticity of epithelial 
cells. The neural crest, a transient structure of the vertebrate embryo delaminates 
from the neural fold through EMT before engaging into extensive migration and 
to subsequently differentiate into the peripheral nervous system, melanocytes and 
in the head craniofacial structures. EMT has also been clearly implicated in heart 
morphogenesis which requires four consecutive cycles of EMT and its reverse 
process Mesenchymal-Epithelial Transition (MET). EMT also plays a major role 
in somite morphogenesis and differentiation to form the striated muscle and the 




Epithelial and mesenchymal cells were first described in the 19
th
 century based on 
their morphology and topological organization in embryos. Epithelial cells are 
characterized by an apico-basal polarity and by the formation of junctional 
complexes called tight junctions next to the apex and adherens junctions and 
desmosomes more basally. The basal domain of epithelial cells is lined by a 
basement membrane separating the epithelium from the mesenchyme.   
Mesenchymal cells are organized as a loose assembly of cells intermingled within 
an extracellular matrix. During the early stages of development, mesenchymal 
cells can exhibit a front-to-end polarity, a morphology that favours migration.  
During EMT, epithelial cells alter their junctional complexes and consequently or 
independently lose their apico-basal polarity. The tight junctional components 
zonula occludens-1 (ZO-1) as well as occludins, claudins and E-cadherin are 
among the first proteins to be targeted during the EMT process. In addition, the 
deregulation or redistribution of major polarity complex components, such as 
Crumbs protein homolog 3 CRB3, lethal giant larvae 2 (LGL2) and partitioning-
defective protein-3/6 (Par-3/6), causes cells to lose their polarity and 
progressively assume a fibroblastic-like morphology to engage in locomotion 
(Thiery 2002). Cytokeratin intermediate filaments connected to desmosomes are 
disrupted and replaced by vimentin intermediate filaments. The actin cytoskeleton 
becomes rapidly altered to ensure the transition in morphology and to initiate 




EMT inducers and effector 
Numerous cytokines and growth factors have been shown to induce EMT during 
embryonic development as well as in in vitro carcinoma cell lines. These factors 
trigger signalling pathways that regulate EMT effectors such as the transcriptional 
repressors of the Snail and Zinc finger E-box binding homolog (Zeb) families and 
Twist basic helix-loop-helix transcription factor (Twist). These transcriptional 
repressors in turn target E-cadherin by binding to the E-box elements proximal to 
E-cadherin promoter; this loss of E-cadherin expression is one of the many 
hallmarks of EMT. Some of these cytokines and growth factors and their role in 
mediating EMT will be discussed in detail in the following sections. 
TGF-β 
The transforming growth factor-β superfamily comprises TGFβ isoforms 
(TGFB1-3), activin (Inha) and inhibins (Inhba, Inhbb, Inhbc, Inhbe), bone 
morphogenetic proteins (BMP2-7), growth differentiation factors (GDF1-15), 
cytokines and their associated receptors. TGFβ signalling is achieved via the 
formation of a heterotetrameric complex of type I and type II serine/threonine 
kinase receptors. The downstream signalling axis can either be receptor regulated 
mothers against decapentaplegic homolog 2/3 (Smad2/3)-dependent or -
independent via the activity of extracellular signal-regulated kinase (Erk), 
Transforming growth factor beta activated kinase 1 (Tak1), c-Jun/p38 mitogen 
activated protein kinase (MAPK) or tumor necrosis factor (TNF) receptor-
associated factor (TRAF)-6. Both signalling axes contribute to EMT via 
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repression of microRNA-200 gene family and the induction of Snail-1, Snail-2, 
Twist and Zeb 1 expression. It is also controlled by repression of miR-491-5, a 
negative regulator of the Par-3 polarity gene. Smad-dependent signalling is 
involved in epigenetic control of EMT through induction of the DNA methyl-
transferase, DNMT1. The TGFβ-Smad3 signalling cascade also cooperates with 
HDAC6 to induce expression of TGFβ1-induced EMT genes. This duo regulates 
cell motility by favouring the acetylation of alpha-tubulin in microtubules. 
(Heldin, Vanlandewijck et al. 2012) 
Wnt 
The Wnt proteins comprise a highly conserved family of secreted signalling 
molecules that play a key role in regulating cell-to-cell interactions during 
embryogenesis. The name derives from the Drosophila Wingless polarity gene. 
The receptors for Wnt consist of members of the Frizzled family and low density 
lipoprotein receptor related protein (Lrp5/6), which are activated upon ligand 
binding. Upon initiation of canonical Wnt signalling, β-catenin escapes 
degradation in the proteasome by dissociating from a complex comprising Axin, 
tumour suppressor, adenomatous polyposis coli and glycogen synthase kinase 3B 
(Axin-APC-GSK3β). The unbound β-catenin then translocates to the nucleus and 
binds T cell factor/lymphoid enhancer-binding factor Tcf/Lef transcription factors 
to activate target genes. Canonical Wnt signalling induces EMT by stabilising 
intracellular levels of Snail-1 and β-catenin. In the absence of Wnt signalling, 
Snail-1 is targeted for proteasomal degradation by β-TrCP-containing E3-
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ubiquitin ligases when phosphorylated by GSK3β. The activation of Wnt 
signalling thus triggers Axin2-dependent nuclear export of GSK3β and increases 
the half-life of nuclear Snail-1. Snail-1 can then regulate the transcription of genes 
that contribute to the EMT programme (Reya and Clevers 2005). 
Notch 
The Notch family consists of four transmembrane receptors (Notch1-4) and five 
ligands (Dll-1, Dll-3, Dll4, Jagged-1 and Jagged-2). These ligands bind to Notch 
residing on adjacent cells for pathway activation. Notch undergoes proteolytic 
cleavage by a complex comprising a TNF-α-converting enzyme and γ-secretase, 
which releases the intracellular Notch domain (ICN). The ICN translocates to the 
nucleus where it binds to C-protein binding factor1 (CSL) to activate the 
transcription of downstream targets.  Notch signalling contributes to EMT via the 
interaction between the ICN/CSL complex with Snail-1 and Snail-2 promoters. 
Notch also induces hypoxia inducible factor (HIF)-1α expression, which binds to 
and activates the lysyl oxidase (LOX) promoter, leading to Snail family protein 
stabilization (Wang, Li et al. 2010).  Notch ligands also up-regulate the 
expression of GATA-binding factors and elevates the expression of EMT 






Epidermal growth factor signalling is initiated when EGF ligands, EGF-like 
proteins and neuregulins bind to their cognate receptors. This results in receptor 
dimerization and autophosphorylation and recruitment of various adaptor proteins 
to elicit downstream signalling. EGF signalling primarily acts through the 
MAPKs, v-akt murine thymoma viral oncogene (Akt) and Jun-amino-terminal 
kinase (JNK) to regulate survival, cell adhesion and cell migration. EGF induces 
EMT by targeting the adherens junction protein, E-cadherin, by various 
mechanisms: EGF signalling stimulates Snail-2 expression to represses E-
cadherin transcription, promotes caveolin-mediated endocytosis of E-cadherin 
(Lu, Ghosh et al. 2003) and stimulates metalloproteinase-dependent cleavage of 
the E-cadherin extracellular domain (Chavez, Buhr et al. 2012). These 
mechanisms provoke the E-cadherin disappearance from cell-cell contacts and 
causes destabilization of the epithelial cell architecture. 
HGF 
Binding of hepatocyte growth factor (HGF)/scatter factor to its receptor (c-Met) 
induces the autophosphorylation of two tyrosine residues, Y1234/1235, in the 
activation loop of the c-Met kinase domain. The subsequent tyrosine 
phosphorylation at Y1349, Y1356 and Y1365 in the c-Met C-terminus creates a 
docking site for adaptor proteins such as growth factor receptor bound protein 2 
associated binding protein 1 (Gab1), growth factor receptor bound protein 2 
(Grb2) and Src homology 2 domain containing transforming protein (Shc) 
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(Schaeper, Gehring et al. 2000). Grb2 and Shc directly bind Ras and activate the 
Ras/Raf/MAPK pathway for morphogenesis, growth and differentiation (Fixman, 
Fournier et al. 1996). Gab1 recruits p85, a subunit of phosphoinositide 3-kinase 
(PI3K) to promote cancer cell survival, among other cellular activities. In 
addition, Gab1 recruits v-crk sarcoma virus CT10 oncogene homolog (Crk), 
which activates the small GTPases ras-related C3 botulinum toxin substrate (Rac) 
and Rap1 for actin cytoskeleton reorganization and cell migration (Lai, Abella et 
al. 2009). Gab1 also recruits p21 protein (Cdc42/Rac)-associated kinase 4 (Pak4), 
a serine threonine kinase, which is essential for cell invasion (Lai, Abella et al. 
2009). In the context of EMT, HGF is involved in up-regulating Snail-1 
expression through the mitogen activated protein kinase/early growth response 1 
(MAPK/Egr-1) signalling axis and Zeb1 expression via repression of miR200c. 
Snail-1, in turn, represses E-cadherin and Claudin-3 gene expression to destabilize 
cell-cell contact, thus favouring cellular scatter. HGF activation also represses 
miR27b, which results in the up-regulation of suppressor of tumourigenicity 14 
ST14/matriptase, an enzyme for extracellular matrix (ECM) degradation, to aid in 
cell migration and invasion during EMT (Susuki, Kimura et al. 2011). 
IGF 
The insulin-like growth factor family consists of two ligands (IGF-1 and IGF-2) 
and three receptors (IGF1R, IGF2R and insulin receptor). Ligands bind to 
receptor 1 to initiate downstream signalling, while receptor 2 acts as a clearance 
receptor for IGF-2. IGF signals through PI3K, which activates the v-Akt murine 
8 
 
thymoma viral oncogene homolog1/mammalian target of rapamycin (Akt/mTOR) 
and c-Jun N-terminal kinases/stress-activated protein kinase (JNK/SAPK) 
pathways for downstream signalling. IGF signalling induces EMT through several 
mechanisms. In the absence of signalling, IGF receptor 1 forms a membrane 
complex with E-cadherin and β-catenin. Ligand binding results in the 
translocation of β-catenin to the nucleus and internalization of E-cadherin at the 
plasma membrane, which then becomes targeted for proteasomal degradation 
(Morali, Delmas et al. 2001). IGF signalling also elevates Snail-1 expression via 
Akt/NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) axis to 
further downregulate E-cadherin expression (Kim, Litzenburger et al. 2007; 
Graham, Zhau et al. 2008; Thiery, Acloque et al. 2009). 
PDGF 
The platelet-derived growth factor ligands (PDGF-A, PDGF-B, PDGF-C and 
PDGF-D) form disulphide linked dimers and bind to PDGF receptors, PDGFRα 
and PDGFRβ, to initiate PDGF signalling. This binding results in receptor 
dimerization and auto-phosphorylation of tyrosine residues that are important for 
downstream signalling. PDGF receptors signal through Ras/MAPK, PI3K and 
phosphoinositide phospholipase C (PLC)-γ signalling axis to modulate cell 
growth and motility (Andrae, Gallini et al. 2008). PDGF signalling induces EMT 
by promoting p68 RNA helicase-mediated nuclear translocation of β-catenin. 
Upon activation, p68 is phosphorylated and displaces Axin from β-catenin, which 
in turn prevents GSK3β-mediated phosphorylation of β-catenin and causes β-
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catenin to translocate into the nucleus to activate the transcription of target genes 
(Yang, Lin et al. 2006). 
VEGF 
The vascular endothelial growth factor (VEGF) family comprises five ligands 
(VEGFA-D, PLGF) and three tyrosine kinase receptors (VEGFR1-3). As with 
other growth factor families, such as the fibroblast growth factor (FGF) family, 
ligand binding results in receptor dimerization and the concomitant interaction 
with specific co-receptors, such as heparan sulphate proteoglycans (HSPGs) and 
neuropilins to activate different signalling modules. VEGF receptors also signal 
through the Ras/MAPK, PI3K and PLC-γ pathways to regulate cell growth and 
migration (Olsson, Dimberg et al. 2006). In the context of EMT, VEGF signalling 
is found to up-regulate a number of mesenchymal markers, such as N-cadherin, 
Snail gene family and vimentin (Gonzalez-Moreno, Lecanda et al. 2010). For 
example, VEGF signalling induces Snail-1 expression by suppressing GSK-3β 
(Wanami, Chen et al. 2008), where Snail-1 in turn represses E-cadherin 
expression to facilitate the acquisition of EMT. 
EMT in cancer 
Metastasis requires that a group of cells or single cells reach and intravasate into 
lymph and blood vessels for dissemination to distant organs. There are currently 
two mechanisms for the spread of cancer to distant sites – collective cell 
migration and single cell migration. Increasing evidence suggests that EMT, a 
mechanism governing morphogenesis and histogenesis, may have been co-opted 
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by cancer cells to facilitate tumour formation and dissemination. A large body of 
data is now supporting this hypothesis for the transition of carcinoma in situ to 
invasive and metastatic stages. However, there are also data showing that 
collective cell migration may contribute significantly to tumour progression. 
Current studies aimed at characterizing circulating tumour cells (CTCs) have 
provided strong evidence for the presence of single cells and cell clusters or 
microemboli. Microemboli may form through the detachment of a group of cells 
in the primary tumour by mechanisms such as engulfment by angiogenic 
endothelial cells or following necrosis in neighbouring cells. Microemboli can 
also form in blood vessels through proliferation in the capillary bed or through 
binding to platelets (Thiery, Acloque et al. 2009; Friedl, Locker et al. 2012; 
Thiery and Lim 2013; Yu, Bardia et al. 2013). 
Microemboli are thought to utilise mechanisms that are distinct from single cell 
invasion mechanisms; however, there exists a possibility that carcinoma cells 
inside or at the leading edge of the invasion zones may undergo partial or 
transient EMT, guiding the invasion of the group of carcinoma cells. Single cell 
invasion, by comparison, requires carcinoma cells at the tumour periphery to 
engage into the EMT programme and delaminate from the primary tumour and 
enter into the blood stream (Thiery 2009). Single cell invasion may enhance 
metastatic efficiency and there is increasing evidence implicating EMT in cancer 
cell dissemination. The EMT process occurs at the invasive front in tumours of 
colon, breast and papillary thyroid carcinoma and produces single migratory cells 
that display the transitioned (‘EMTed’) expression profile. Cancer cells also 
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alternate between EMT and MET states to increase tumour spread along the walls 
of the colon, stomach and peritoneal cavity.  
 
Figure 1: Illustration of the 2 mechanisms of cell invasion during metastasis. 
Collective cell migration describes the presence of a group of cells, termed 
microemboli that form by A) engulfment of carcinoma cells by angiogenic endothelial 
cells; B) detachment of a group of cells from the primary tumour; C) proliferation in 
the capillary bed or through binding to platelets. Single cell migration describes the 
presence of single cells in the blood stream caused by D) epithelial-mesenchymal 
transition, a process in which cells assume a mesenchymal morphology and detach 
from the primary tumour intravasate as single cells in the blood/lymph vessels. 
Microemboli and single cells extravasate and form micrometastases at secondary 




The acquisition of EMT may confer chemoresistance in carcinoma cells and thus 
result in failure of chemotherapy treatment (Marchini, Fruscio et al. 2013). 
Carcinoma cells which escape treatment by chemotherapy often exhibit the 
mesenchymal phenotype. Furthermore, studies show that miRNAs that are 
responsible for negatively regulating EMT effectors are repressed in 
chemoresistant carcinoma cells as well as in patients with poor survival (Hu, 
Macdonald et al. 2009; Cochrane, Howe et al. 2010; Feng, Wang et al. 2012). 
Indeed, forced expression of the repressed miRNA can restore chemotherapeutic 
sensitivity in chemoresistant cells (Cittelly, Dimitrova et al. 2012). Thus, 
therapies directed toward abrogating the onset of EMT in cells or reversing its 
process may contribute to improved prognosis in susceptible, chemoresistant 
cancer patients.   
 
Tumour microenvironment and growth factors 
As a first step in metastatic processes, cells of the primary tumour may undergo 
EMT, directed by interaction with the tumour microenvironment. The tumour 
microenvironment consists of endothelial cells, tumour-associated stromal cells 
(TASc), infiltrating immune cells and ECM proteins. TASc are fibroblastic cells 
that surround or are present in the tumour and release inducers of EMT such as 
EGF, HGF and TGFβ. These factors bind to their cognate receptors present on 
cancer cells and elicit a change within signalling pathways to induce EMT. TASc 
also release VEGF and stromal cell-derived factor (SDF) to support the growth of 
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endothelial cells and pericytes, both of which are essential for the formation and 
maintenance of angiogenesis within the tumour. These blood vessels provide a 
route for EMTed cancer cells to escape the primary tumour and to disseminate to 
secondary sites.  
The infiltrating immune cells consist of T cells, cells of the B cell lineage, 
macrophages and myeloid-derived cells. CD8
+ 
cytotoxic T cells and CD4
+
 Th1 T 
cells, as well as the production of cytokine interferon (IFN)-γ, function as the 
major anti-tumoural immune effectors. However, a specialized subset of CD4+ T 




 regulatory T cells (TRegs), can hamper the anti-
tumoural immune response and contribute to tumour evasion. Tumour-associated 
macrophages (TAMs) or myeloid-derived suppressor cells (MDSCs) and their 
derived cytokines (TNF and interleukins IL-6, IL-1β and IL-23) are recognized as 
drivers of tumour promotion. These TAMs and MDSCs also release soluble 
ligands, including TGFβ and HGF, which bind to their respective receptors to 
elicit the EMT programme, further aiding in tumour dissemination. 
The ECM serves as a reservoir for growth factors and various ECM proteins are 
thought to play different roles in modulating growth factor signalling. ECM 
proteins for example, heparin sulphate proteoglycans (HSPGs), fibronectin, 
tenascin-C and neural cell adhesion molecule (N-CAM) can increase the local 
concentration of the growth factors by ensuring their bioavailability. One 
important type of ECM proteins is the HSPGs. In addition to their role in 
facilitating signalling, HSPGs also act as ‘fly-traps’ for free growth factors in the 
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ECM, such as FGF and VEGF. These ligands can be released following the 
activity of the HSPG-specific enzyme heparanase, which cleaves 
glycosaminoglycan components of HSPGs and releases them and any bound 
molecules into the ECM. There are various other ECM proteins that interact with 
free growth factors via specific domains within their amino acid sequence. For 
example, fibronectin and tenascin-C contain FnIII domains to which VEGF can 
bind and potentiate signalling through VEGFR2 (Wijelath, Rahman et al. 2006).  
Fibronectin and vitronectin also bind HGF and form complexes with c-MET to 
activate c-MET signalling (Kim, Turnbull et al. 2011). Other protein domains 
within ECM proteins can act as non-canonical ligands for growth factor receptors; 
for example, the FnIII domain of neural cell adhesion molecule (NCAM) binds to 
FGFR1 to elicit ligand-independent receptor phosphorylation  (Kiselyov, 
Skladchikova et al. 2003). Similarly, EGF-like domains in laminin and 
thrombospondin bind directly to EGF receptors as soluble ligands to modulate 
EGF signalling (Schenk, Hintermann et al. 2003). 
In situ tumours are surrounded by a basement membrane consisting mainly of 
numerous structural ECM components, including proteoglycans, type IV 
collagen, and laminins, which function to physically segregate the pre-invasive 
tumour epithelia from the vascular structures within the stroma. However, studies 
have shown that signalling by various growth factors and cytokines can in fact 
enhance the expression and activity of matrix metalloproteinases (MMPs) and 
enzymes to disrupt the tumour capsule and facilitate metastasis. MMPs are zinc-
dependent endopeptidases present within the ECM that are normally expressed 
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only during stages of tissue repair and remodelling. However, recent studies have 
implicated the expression of MMPs during the various stages of cancer 
progression. Indeed, upon basement membrane disintegration, the tumour mass 
penetrates the surrounding stroma, leading to local invasion and an increase in the 
blood supply for the tumour.  
It is largely unknown which factors are involved in guiding tumour cells to a 
specific tissue. However, recent studies demonstrate the role of a pre-metastatic 
niche, where bone marrow-derived hematopoietic progenitor cells act to initiate 
early changes within the ECM and create a favourable microenvironment for 
tumor growth at distant tissue sites (Psaila, Kaplan et al. 2006). Extracellular 
proteins also play key roles as metastasis niche components for tumour-initiating 
cells during tissue invasion. The pre-metastatic niche provides an array of 
cytokines, growth factors, and adhesion molecules to support the arrival of 
metastatic cells. Before tumour cells colonize distant organs, the primary tumour 
releases VEGFA, which directs VEGFR1+ myeloid cells to mobilize to distant 
pre-metastatic sites (Kaplan, Riba et al. 2005). Other soluble factors, such as 
TGF-β and TNF-α, together with VEGFA, are released by the primary tumour to 
induce the expression of the inflammatory chemoattractants S100A8 and S100A9 
(Hiratsuka, Watanabe et al. 2006) and signal transducer and activator of 
transcription 3 (Stat3), which activates fibroblasts at the pre-metastatic site, 
leading to an increase in the production of fibronectin. The upregulation of 
S100A8 and S100A9 attracts mac1+ bone marrow-derived cells to the pre-
metastatic site (Rafii and Lyden 2006) and together attract tumour cells to 
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metastasize (Cheng, Corzo et al. 2008). It is the combination of this specific up-
regulation of fibronectin and clustering of bone marrow-derived cellular infiltrates 
at distant sites that creates the pre-metastatic niche (Peinado, Aleckovic et al. 
2012).   
This concept has been well demonstrated in the lungs. The matricellular protein 
periostin has been shown to concentrate Wnt ligands within the metastastic niche 
to stimulate metastasis-initiating cells and enhance tumour colonization in the 
lungs. Tenascin-C, an ECM glycoprotein, also functions to sensitize cancer cells 
to Wnt and Notch signalling, thereby supporting the survival and fitness of the 
metastasis-initiating cells (Oskarsson and Massague 2012).   
 
 
The bladder  
The urinary bladder is a hollow, muscular organ situated at the front of the pelvic 
floor, behind the symphysis pubis and below the peritoneum. It is connected to 
the two kidneys via the ureters, and functions as a reservoir to collect and expel 
the urine excreted by the kidneys via the urethra. The bladder muscles then help 
to eliminate urine by expanding and contracting the organ. The ureters and 
urethral openings outline a triangular region, the trigonum vesicae, at the interior 
base of the bladder. The neck of the bladder is the lowest part of the organ 
immediately surrounding the urethral opening. The top surface of the bladder is 
triangular and is covered with peritoneum. The bladder is supported on the levator 
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ani muscles, which constitute the major part of the floor of the pelvic to keep the 
bladder and other pelvic organs in position.  
 
Figure 2: Illustration of the 
urinary system.  
The urinary system is made up 
of two kidneys linked to the 
urinary bladder via two ureters 
and an outlet known as the 
urethra, which is used to expel 
urine out of the body. The 
urinary bladder is a hollow, 
muscular organ that lies at the 
front of the pelvic floor. The 
bladder comprises the bladder 
wall, bladder cavity and the 
trigonum vesicae, situated at 
the interior base of the bladder. 
The bladder functions to act as 
a reservoir for storage of urine 
prior to its elimination from the 
body. 
The bladder is supplied by the superior, middle and inferior vesical arteries. The 
superior vesical artery delivers blood to the dome of the bladder, while the middle 
vesical artery supplies blood to the base of the bladder. The inferior vesical artery 
provides blood supply to the inferolateral surfaces of the bladder and also the base 
of the bladder and the lower end of the ureter.  
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The bladder is innervated by sympathetic and parasympathetic ganglia of the 
autonomic nervous system. The sympathetic nerves carry the sensations 
associated with distension of the bladder to the nervous system and may also 
participate in relaxation of the muscular layer and contraction of the sphincter that 
closes the urethral opening. Parasympathetic nerves are involved in contraction of 
the muscular layer and relaxation of the sphincter. Both nerves are required for 
urination.  
Structure of the bladder wall  
The bladder is composed of four layers: mucosa, submucosa, muscular and 
serosa.  
 
Figure 3: Illustration of the bladder wall. 
The bladder wall consists of 4 layers: mucosa, submucosa, muscular and serosa. 
Mucosa consists of the transitional epithelium and houses the transitional cells and a 
single layer of umbrella cells that make the bladder wall impermeable to water and 
ions. Submucosa serves to maintain the structural shape of the bladder. Muscular layer 
helps to contract the bladder while voiding. Serosa is the outer most layer of the 






The mucosa, or the urothelium, is a transitional epithelium consisting of 
superficial, intermediate and basal cell zones, which lines the bladder and is 
impervious to urine. The superficial cell layer contains a single layer of umbrella 
cells, which are large often binucleated. Umbrella cells are histologically distinct, 
characterised by a specialized apical plasma membrane in which the outer leaflet 
appears twice as thick as the inner one. The surface plasma membrane consists of 
thickened inflexible plaques, often termed the asymmetrical unit membrane, 
which is interspersed with narrow zones of normal membrane. This structure 
allows the umbrella cells to expand greatly and quickly when the bladder is 
distended. The umbrella cells are characterized by well-developed tight junctions 
that serve to resist paracellular ion flux (Lewis, Eaton et al. 1976; Truschel, Ruiz 
et al. 1999). The apical membrane is highly impermeable to water and solutes, 
and contains an array of glycosaminoglycans which may prevent bacterial 
adhesion (Parsons, Boychuk et al. 1990; Chang, Hammond et al. 1994). The 
intermediate cell zone consists of several layers of cuboidal-to-low columnar cells 
with regularly arranged nuclei, well defined borders and amphiphilic cytoplasm 
that is rich in glycogen. The basal layer consists of a single layer of cells in 
contact with the basement membrane, a sheet of extracellular material that 
provides structural support for the mucosal layer. Basal cells are more cylindrical 
and perpendicularly oriented to the plane of the basement membrane.  
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The submucosa, also known as the lamina propria, is situated between the 
mucosal basement membrane and the muscular coat. The lamina propria consists 
of loose-to-dense connective tissue with blood vessels, nerves, and glands in some 
regions. The superficial lamina propria contains the capillary network of the 
bladder, surrounded by a dense layer of collagen fibers, whereas the deeper 
lamina propria contains a thick layer of collagen type I fibers. The lamina propria 
creates a connective tissue matrix that functions to maintain the structural shape 
of the bladder wall.  
The detrusor muscular coat, commonly termed the muscularis propria, houses 
muscle fiber bundles that provide contraction capabilities to aid in voiding. The 
muscularis propria consists of smooth muscle cells surrounded by an ECM 
comprising collagen and elastic fibrils that form muscle fiber bundles. It is 
subdivided into inner longitudinal, middle circular and outer longitudinal layers of 
thick muscle bundles. The muscle layers are distinct only near the bladder neck; 
the three layers are difficult to distinguish in the remaining areas, as the 
longitudinal and circular layers mix freely without definite orientation.  
The serosa is the outermost layer of the bladder wall and is derived from the 
peritoneum, covering only the upper and lateral surfaces of the bladder. Fibrous 
adventitia, a layer of areolar connective tissue, covers the posterior and anterior 
surfaces of the bladder wall. These two layers help to hold the bladder in position 
and reduce friction with neighbouring organs. There is also a layer of fat, known 




Bladder cancer is the most common cancer in the Middle East and Africa, the 
fifth most common in the Western world and the tenth most common amongst 
males in Singapore. The age standardized rate of bladder cancer is four times 
higher in men compared with women. Bladder cancer is the second most 
frequently diagnosed of the genitourinary cancers.  
Bladder cancer describes the malignancy of cells residing in the bladder wall. The 
type of bladder cancer is characterized by the type of cells affected amongst the 
various several layers of the bladder wall. Transitional cell carcinoma arises from 
the clonal expansion of genetically altered but histologically normal cells from the 
mucosa (Crawford 2008). These transitional cells (intermediate cell zone) 
function to allow the bladder to stretch when full and shrink when empty. Long-
term irritation of the bladder by infectious agents or foreign bodies cause the 
transitional epithelium to change into squamous or flattened cells, which gives 
rise to squamous cell carcinoma. Adenocarcinoma arises from malignancy in the 
cells that make up the mucus-secreting glands in the bladder.  
The associated risk factors for developing bladder cancer are smoking and 
chemical exposures at work. Smoking is associated with over 50% of bladder 
cancer cases in men and 52% in women (Freedman, Silverman et al. 2011). A 
linear relationship exists between tobacco smoking and the risk of developing 
bladder cancer (Boffetta 2008). The chemical 2-Naphthylamine in cigarette smoke 
has been shown to increase bladder cancer risk. In addition, exposure to chemical 
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carcinogens, such as benzidine, in the workplace greatly increases the risk of 
bladder cancer. People in occupations that deal with dyes, leathers, rubbers, 
pesticides and fertilizers are predisposed for bladder cancer. Another risk factor 
for the development of bladder cancer is schistosomiasis, a parasitic disease 
caused by several species of trematodes. Schistosoma embed their eggs into the 
lamina propria and muscularis propia of the bladder wall and provoke a severe 
inflammatory response and fibrosis, thus increasing the risk of bladder cancer. In 
areas with low prevalence of schistosomiasis, 90% of diagnosed bladder cancers 
are transitional cell carcinoma, with the remaining 10% are squamous and 
adenocarcinoma. However, in areas where there is a high prevalence of 
schistosomiasis, such as Egypt, Sudan and countries in the east Africa, squamous 
cell carcinoma is the most frequent type of bladder cancer. 
Various genetic alterations, such as mutations in v-Ha-ras Harvey rat sarcoma 
viral oncogene homolog (H-Ras), v-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (K-Ras), neuroblastom RAS viral (v-ras) oncogene homolog (N-Ras), 
Fibroblast growth factor receptor 3 (FGFR3), (Phosphatidylinositol-4,5-
biphosphate 3-kinase, catalytic, alpha polypeptide (PIK3CA) and tumour protein 
p53 (p53) have been found associated with an increased risk of bladder cancer 
(Kompier, Lurkin et al. 2010). FGFR3 and p53 alterations are mutually exclusive, 
and they characterize two different genetic pathways in urothelial cell carcinoma 
pathogenesis (van Rhijn, van der Kwast et al. 2004). FGFR3 mutations are 
frequently found in low-stage or low-grade tumours and are related to favourable 
disease outcome. On the other hand, p53 mutations are frequently found in 
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invasive urothelial cell carcinoma as well as in high-grade superficial tumours, 
including carcinoma in situ, the putative precursor of invasive urothelial cell 
carcinoma. Patients with p53 mutations present with adverse disease parameters 
and poor prognosis. In addition to these genetic alterations, bladder cancer 
patients who exhibit high expression of autocrine growth factor receptors have 
significantly lower survival rates (Korman, Peabody et al. 1996). 
 
Diagnosis and treatment 
The most common signs of bladder cancer are hematuria (blood or blood clots in 
the urine) as well as voiding symptoms and pain that develop above the pubic 
bone or in the flank region due to pressure of the urine against the back. Thus, 
urine tests, imaging tests and cytoscopy are used to aid in the detection of bladder 
cancer. Urine cytology is used to detect for abnormal cells that shed from the 
lining of the bladder. Cytoscopy serves as a tool to examine the lining of the 
bladder and urinalysis is used to detect for the presence of white and red blood 
cells under the microscope. Other laboratory tests, such as BTA Trak and BTA 
Stat assays are conducted to detect the bladder cancer biomarker bladder tumour-
associated antigen (BTA) in urine samples. Nuclear Matrix Protein No.22 (NMP-
22) is another urinary marker of bladder cancer that can be detected using 
commercial assays. Tumour masses are detected using intravenous pyelogram 
(IVP), an x-ray examination. In this procedure, the injected radiopaque dye 
24 
 
(contrast agent) collects in the kidney and gets excreted into the bladder. X-rays 
are taken as the dye moves through the urogenital system to examine the structure 
of the bladder and detect the presence of abnormal masses. Computed 
tomography (CT) scanning is also used to detect masses and determine if the 
cancer has spread to other regions. Biopsy is used to excise any abnormal tissue if 
observed, which is processed for histological examination to confirm or exclude 
the presence of cancer cells. 
Staging of bladder cancer is determined by the TNM (tumour, node, metastasis) 
method of classification. The tumour (T) stage describes the layers of tissue 
affected within the bladder wall. Ta, T1 and Tis stages describe early bladder 
cancer in which cancer cells have not invaded into the muscle layer, while T2, T3 
and T4 describe later stages of cancer progression. Ta is used to describe a non-
invasive papillary carcinoma found on the inner lining of the bladder, whereas T1 
refers to a tumour embedded within the lamina propria but not yet invaded the 
muscle layer. Tis describes non-invasive flat carcinoma (flat carcinoma in situ, 
CIS) Ta and T1 tumours form mushroom-like protrusions while Tis (CIS or 
carcinoma in situ) forms flat lesions on the inner lining of the bladder. The flat 
lesions comprise cells in the mid- to upper epithelium with high cytologic grade. 
T2 describes a tumour that has invaded into the muscle layer, T3 describes tumour 
growth through the muscle layer into the fatty layer surrounding the bladder, and 
T4 describes tumour growth that has disseminated from the bladder to other 
organs. The second part of the classification involves the lymph node (N) stages, 
describing the number of involved lymph nodes and the region affected. N0 
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describes no cancer found in any lymph nodes, N1 refers to one affected lymph 
node in the pelvis, N2 refers more than one lymph node affected in the pelvis, and 
N3 refers to one or more lymph nodes affected in the groin. Finally, the metastasis 
(M) stage describes the spread of the cancer to another organ. M0 refers to no 
metastasis whereas M1 refers to metastasis found in other parts of the body, 
usually the bones, lungs or liver.  
The grade of bladder cancer is determined by the morphology and growth rate of 
the cells. Grade 1 cancers have cells that display normal cell morphology and are 
slow growing. Grade 2 cancers comprise moderately differentiated cells that 
proliferate faster than those in low-grade tumours. Grade 3 cancers have poorly 
differentiated cells with even higher proliferative rates.     
Advanced bladder cancer, known as invasive bladder cancer, consists of T2, T3 
and T4 tumours. Patients with invasive bladder cancer are treated with radial 
cystectomy and proximal lymph node removal. This is followed by chemotherapy 
and radiation to lower the chance of relapse at a distant site. In more advanced T4 
tumours, bladder cancer is treated with chemotherapy to shrink the primary 
tumour before radial cystectomy and radiation therapy.  
Various chemotherapeutic agents are used in combination for the treatment of 
bladder cancer. The three main chemotherapeutic regimens for invasive bladder 
cancer are CISCA, CMV and MVAC. The CISCA regimen is a combination of 
Cisplatin, Doxorubicin and Cyclophosphamide for a cycle of 21-28 days 
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(Sternberg, Bracken et al. 1977). The CMV regimen consists of a combination of 
Cisplatin, Methotrexate and Vinblastine for a cycle 21 days (Harker, Meyers et al. 
1985). The MVAC regimen is a combination of Methotrexate, Vinblastine, 
Doxorubicin and Cisplatin for a cycle of 28 days (‘chemo regimen’). For non-
invasive, high-grade bacillus Calmette-Guerin (BCG)-refractory bladder cancer, 
sequential intravesical combination chemotherapy consisting of gemcitabine and 
mitimycin C is used (Lightfoot, Breyer et al. 2013). 
 
Figure 4: Illustration of bladder cancer tumour stages.  
Bladder cancer is staged using the TNM (tumour, nodes, metastatsis) classification 
system. ‘T’ is followed by numbers and/or letters to describe the extent to which the 
primary tumour has grown through the bladder wall. Tis: Non-invasive flat carcinoma 
(flat carcinoma in situ, CIS); Ta: non-invasive papillary carcinoma; T1: the tumour has 
grown from the inner lining of the bladder to the lamina propria but not yet invaded the 
muscle layer. T2: The tumour has grown into the muscle layer. T3: the tumour has 
grown past the muscle layer into the fatty layer. T3a: the tumour spread to the fatty 
tissue can only be seen by using a microscope. T3b: the tumour spread to the fatty 
tissue is large enough to be detected by imaging tests or seen/felt by the surgeon. T4: 
tumour has spread beyond the fatty layer. 
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Bladder cancer and growth factors 
 
Growth factors contribute to tumorigenesis by increasing tumour cell 
proliferation, angiogenesis and invasion. Certain growth factors and their cognate 
receptors have been found associated with bladder cancer progression. For 
example, EGFR was first characterized in superficial and invasive bladder cancer 
in 1989 (Smith, Fennelly et al. 1989).  The over-expression of wild-type EGFR 
and abnormal secretion of EGF preceded the physical detection of transitional cell 
carcinoma. The degree of EGFR over-expression in bladder tumours correlates 
with the tumour stage and grade (Khaled, Bahnassy et al. 2009). 
Activating point mutations of FGFR3 have also been identified in approximately 
75% of low-grade and low-stage bladder carcinoma. Mutations in FGFR3 are 
common in papillary bladder cancers, suggesting that FGFR3 mutations occur 
early in the development of non-invasive bladder cancer (Cappellen, De Oliveira 
et al. 1999; Hernandez, Lopez-Knowles et al. 2006). Up regulation of FGFR 
signalling is also detected in tumours with oncogenic FGFR3 gene fusions 
(Williams, Hurst et al. 2013).  
Elevated levels of HGF have been detected in the serum and tissues of patients 
with bladder cancer. Muscle-invasive cancer patients have higher serum levels of 
HGF than do superficial cases. Among all bladder cancer patients, those with 
metastatic bladder cancer have the highest levels of HGF in the serum and tissue. 
Decreased disease-free period and overall survival rates are reported for patients 
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with high serum levels of HGF as compared to those with similar disease state but 
lower HGF serum levels (Smolen, Sordella et al. 2006). 
Since haematuria is usually associated with advanced bladder cancer, the VEGF 
pathway is to be critically important in the process of angiogenesis. Studies have 
shown that protein expression of VEGF in bladder cancer tissues and serum levels 
of VEGF correlate with increased tumour stage (Bernardini, Fauconnet et al. 
2001; Yang, Chu et al. 2004). In particular, VEGFR2 expression correlates with 
pathological stage in human urothelial carcinoma cell lines and bladder tumours 




In this thesis, an in vitro bladder cancer model was used to investigate the 
interaction of microenvironment and carcinoma cells. Chapter 1 describes the 
establishment of an in vitro bladder cancer model that readily engages EMT when 
induced. When NBT-II carcinoma cells are challenged with EGF and HGF, NBT-
II carcinoma cells not only undergo EMT but also express a common set of genes 
that is responsible for tumour progression. Interestingly, some of the EGF and 
HGF regulated genes are highly associated with invasive bladder cancer. The role 
HGF play in bladder tumour progression is further examined. The transcriptomics 
of NBT-II carcinoma cells at multiple time-points after HGF induction was 
investigated. The level of transcriptional activity is highest during the window 
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from which the cells disperse to the point they gain motility. Expression profiling 
analysis indicates that HGF initiates other signal transduction pathways to acquire 
and sustain a mesenchymal phenotype. A downstream effector, Smad2 is 
implicated in this HGF induction system and is regulated by both MAPK and 
TGFbR1. This chapter also describes the difference in the role of the linker and 
C-terminus region of Smad2.  
Chapter 2 is divided into 2 parts. The first part of Chapter 2 describes an EMT 
inhibitor screen in which small molecular weight kinase inhibitors were utilised to   
interfere with downstream signalling systems to c-Met (HGFR). This screen 
identified inhibitors that target c-Met, MEK, PI3K and TGFRβ.  The shortlisted 
inhibitors were able to block EMT and transwell migration. In the second part of 
Chapter 2, we utilised an in vivo orthotopic bladder cancer mouse model to test 
the potential of a TGFβRI inhibitor in delaying cancer progression. The in vivo 
model shows that carcinoma bladder wall invasion was delayed in inhibitor 
treated mouse. In chapter 3, the significance of these findings and the impact they 







Chapter 2: Experimental procedures 
Cell lines and culture conditions 
The transitional cell carcinoma cell lines HT1376, J82, NBT-II, T24, TCCSUP, 
UM-UC-3 were obtained from the American Type Culture Collection (ATCC; 
catalog no. CRL-1472, HTB-1, CRL-1655, HTB-4, HTB-5, CRL-1749). Cells 
were routinely cultured in Dulbecco’s Modified Eagle Medium (Gibco, Life 
Technologies) supplemented with 10% fetal bovine serum (FBS, HyClone 
Thermo Scientific), 1 µg/ml puromycin (Sigma) and 100 units/ml penicillin-
streptomycin (1× pen-strep, Invitrogen). Cultured cells are regularly tested for 
mycoplasma contamination. 
 
Reagents and preparation of compound plates 
For each growth factor-induced EMT in NBT-II cells, we optimized the final 
growth factor concentrations to be 20ng/ml EGF (Sigma), 4ng/ml HGF 
(Calbiochem) for EMT inhibitor screen, 5 ng/ml HGF for all other experiments 
and 150ng/ml IGF-1 (R&D Systems).  
Test compounds were purchased from various vendors (Selleck Chemicals, Sigma 
Aldrich, SYN|thesis MedChem, and Tocris Bioscience). Compound stocks were 
assembled in 96-well V-bottom plates (Greiner). For screening studies, test 
compounds at both 0.25 mM and 1.0 mM concentrations in DMSO were 
prepared, with each occupying a single well in columns 2–11 of the stock plates. 
For dose response studies, test compounds were prepared in duplicate wells and 
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serially diluted in DMSO, starting with a 1.0 mM concentration. Stock plates 
were stored at −20oC and thawed to room temperature before use. 
 
Stable transfection 
NBT-II were stably transfected with mcherry-fluorescent H2B plasmid (Addgene 
deposited by Robert Benezra) using lipofectamine2000, according to 
manufacturer’s protocol (Invitrogen), followed by selection for single clones by 
supplementing 1mg/ml neomycin (Sigma) to the medium.  
NBT-II/ UM-UC-3 were stably transfected with Smad2dnL and Smad2dnC 
plasmid (Addgene deposited by Joan Massague and Rik Derynck) using 
lipofectamine2000, according to manufacturer’s protocol (Invitrogen), followed 
by selection for single clones by supplementing 1ug/ml puromycin (Invitrogen) to 
the medium.  
UM-UC-3 were stably transfected with pGl4.51 luciferase 2/CMV vector 
(Promega) using lipofectamine2000, according to manufacturer’s protocol 
(Invitrogen), followed by selection for single clones by supplementing 1mg/ml 
neomycin (Sigma) to the medium. Luciferase activity was measured with 





NBT-II cells were seeded at a density of 100 cells per well on Ibidi 8 well μ-slides 
and grown for four days to form colonies. Cells were pre-treated with HGF or 
EGF and then fixed with 4% paraformaldehyde and stained with mouse anti-rat 
Desmoplakin (Millipore; clone DP2), mouse anti-human Vimentin (Abcam; clone 
V9) and mouse anti-Smad2/3 (BD Transduction Laboratories; clone 18/Smad2/3) 
primary antibodies. A goat anti-mouse antibody conjugated to Alexa Fluor 488 
(Invitrogen) was used as a secondary antibody. Fluorescent images were captured 




Total RNA was purified from NBT-II cells using RNeasy mini kit (Qiagen). RNA 
concentration was determined using NanoDrop 1000 Spectrophotometer 
(Thermoscientific) and RNA integrity was measured using the Agilent 
Bioanalyzer 2100 (Agilent). 5ug of total RNA was used to generate sense-strand 
cDNA using Ambion® WT Expression Kit protocol (Ambion) with Applied 
Biosystems Vertic 96 well Thermal Cycler (Applied Biosystems) followed by 
fragmentation and labelling using the Affymetrix GeneChip® WT Terminal 
labelling kit protocol (Affymetrix) before loading onto the Affymetrix Rat Gene 
1.0st Array (Affymetrix). The probe array was incubated for 16 hours at 45
o
C at 
constant rotation (60r.p.m). The washing and staining procedure was performed in 
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the Affymetrix Fluidics Station 450 (Affymetrix). Microarrays were then scanned 
using GeneChip® Scanner 3000 7G (Affymetrix).  
 
DNA microarray data analysis 
Probe set intensities were normalized with unified efficient Lowess correction 
(Ballman, Grill et al. 2004). Normalization was performed on all 24 microarrays, 
followed by a log2 transformation. Log2 probe intensities of below 6 were filtered 
off from the analysis. About 53% of the probe-sets pass as present in each sample. 
Significant genes were chosen with criteria of FDR 0.01 and a minimum fold 
change of 1.2. 
 
Gene score analysis – finding Differentially Expressed Genes (DEG) 
The method reported by Zeisel A et al (Zeisel, Amir et al. 2010) was used to 
estimate intensity-dependent noise in the data and to estimate p-values. This 
method assumes that the noise in the data has a normal distribution and is 
intensity dependent. Genes were filtered according to temporal variation to find 
genes that have at least one time point with a fold change of at least 2 compared 
to its initial value at t=0. P-values for differential expression of each gene, at 
every time-point – comparing treated vs. control, based on intensity-dependent 
estimation of the noise was computed. An improved Benjamini-Hochberg 
(Benjamini and Hochberg 1995) estimate of the False Discovery Rate (FDR) was 
used (Zeisel, Zuk et al. 2011) Genes with FDR below 0.05 and with a minimal 
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fold change value of 1.5 at the specific time-point were identified as DEGs. Gene 
score was computed: score= number of time-points at which a given gene is 
differentially expressed. 
 
Functional annotation and pathway enrichment analysis 
In order to assign biological interpretation to gene lists, gene set enrichment 
analysis was performed using the DAVID online tool, to identify both 
significantly dominant biological processes and pathways (Huang da, Sherman et 
al. 2009) (Huang da, Sherman et al. 2009) 
 
Wound healing assay 
NBT-II cells were seeded at a density 2x10
5
cells/ml in each well of a 12 well-
plate (NUNC) and transfected with 20nM of siRNA (Smad2, Smad3 and Smad4) 
(Qiagen) for 48 hours. 3 wounds were made for each sample using a yellow 
pipette tip, and wound closure was imaged at 0 hour and after 24 hours. Area of 
the wound was measured using ImageJ software. Total area migrated by the cells 
was calculated by subtracting the area measured at 24 hour from the area of the 





NBT-II cells were seeded at a density of 0.5 x10
6
 cells per 10cm cell-culture 
treated dish (NUNC) and grown for four days to form colonies. Cells were pre-
treated with HGF or HGF + A83-01 before harvesting. Cells were tripsinized and 
the number of cells in each sample was quantified. Equal number of cells was 
pelleted for each sample. Fractionation was performed using Qproteome cell 
compartment kit (Qiagen), according to manufacturer’s protocol. 
  
Transwell assay/Boyden chamber 
 5 x105 of cells were seeded on Matrigel (BD biosciences) coated polycarbonate 
membrane insert (6.5 mm in diameter with 8.0um pores) that hung above medium 
supplemented with or without HGF in a Transwell setup (Costar) and incubated 
for 24 hours at 37°C. The upper side of the insert was swiped with cotton bud to 
remove the non-motile cells and the cells at the underside of the insert were 
stained with calcein AM (Invitrogen) for an hour in the incubator. The stained 
cells were then trypsinized and the number of migrating cells in each well was 
quantified by fluorescence reading using Tecan100 (Tecan).  
 
Spot migration assay 
NBT-II cells were trypsinized and concentrated to a density of 5×10
6
 cell/ml in 
CO2-independent medium (Invitrogen) supplemented with 10% FBS. The cell 
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suspension was then evenly dispensed into the wells of 2 columns of a 96-well V-
bottom plate. Using a robotic liquid-handling station (Bravo, Agilent 
Technologies), 0.5 µl of cell suspension was transferred from the 2 columns of the 
cell suspension-loaded plate and deposited into the center of the wells of 2 
columns of a blank 96-well polystyrene tissue-culture treated clear bottom, black 
assay plate (Corning #3904). This process was repeated six times so that all 96 
wells of the assay plate were deposited with a cell suspension spot. The plate was 
then sealed to minimize evaporation of the cell suspension spots and transferred to 
a 37
o
C, 5% CO2 incubator to allow for cells to attach to the culture surface. After 
1 hour, the plate was gently washed with medium once to remove unattached cells, 
refreshed with 100 µl of assay medium (DMEM supplemented with 10% FBS and 
1× pen-strep), and then further incubated to allow for cell-cell contacts to 
establish in the cell colonies. 
After 4 hours of incubation, the cell colonies for each well were imaged using a 
confocal microplate imager (MetaXpress Ultra, Molecular Devices) with 10×Plan 
Fluor objective, 561 nm laser excitation and 593/40 nm emission filter 
configuration. Four tiled, non-overlapping images were acquired around the 
center of each well, and were then stitched together during image analysis to 
generate a montage covering an area of 3.2 mm×3.2 mm. These images (T1) 
represent the initial state of the cell colonies before EMT induction. 
After the T1 images were acquired, 1 µl of test compounds were transferred from 
compound stock plates and added to the assay plates. Appropriate negative 
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controls (1 µl DMSO) and positive controls (1 µl 1.0 mM compound in DMSO) 
were also added into columns 1 and 12 of each assay plate, respectively. The 
assay was optimized to use AG1478, JNJ-38877605 and BMS-536924 as 
reference positive control compounds for EGF-, HGF- and IGF-1-induced EMT, 
respectively. The cultures were then further incubated overnight. 
The next day, 50 µl of growth factor-containing medium was added to each well 
of the assay plates. The cultures were then incubated for another 24 hours, to 
allow for EMT and sufficient cell motility/dispersion to occur in the cell colonies. 
Finally, the cell colonies were imaged again using the microplate imager, as 
described above. These images (T2) represent the final state of the cell colonies 
after compound treatment and EMT induction. The acquired T1 and T2 image 
sets for each assay plate were then sent for image analysis. 
Image analysis routine 
The acquisition of each well was obtained by four adjacent field images with no 
interstice in between. Each field image was loaded and nuclei were initially 
segmented independently of other fields to prevent artifact at the field border. 
Nuclei segmentation was achieved by combining a wavelet transform which is 
robust to noise and inhomogeneous background, and a watershed algorithm based 
on intensities to split nuclei clusters. Mask of nuclei segmentation of the different 
fields were then stitched together in order to obtain a large segmentation of the 
whole well. Cell bodies were estimated by applying a morphological dilation on 
the nucleus segmentation using a disk of 30 pixels (48 µm) in diameter. In cells 
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that were contiguous, such as in a cell colony, nuclei segmentation dilation will 
result in the formation of continuous region areas with surrounding cells which 
can then be identified as colonies. In general, a well will contain one big colony 
(corresponding to the initial cell spot) and several much smaller colonies 
(corresponding to single cells, small cluster of cells, dust and contamination). 
Only nuclei contained in the biggest colony were kept and subsequently analysed. 
A spreading coefficient was derived from nuclei positions in order to measure 
how much the colony had dispersed. The spreading coefficient is defined as the 
standard deviation of the cell positions in the cell colony relative to the center of 
the colony: 
 
where Col indicates all cells of a colony, #Col is the total cell number,  [Colx, 
Coly] is the average position of all nuclei in the colony, [cx, cy] is the position of 
the cell c. The coefficient sp is homogenous with a distance and indicates the 
relative cell dispersion from the colony center. 
Total cell number and spreading coefficient values for each well were exported 
into an Excel sheet. The Cell Count Ratio (CCR) and Cell Dispersion Ratio (CDR) 
values were calculated by combining data calculated from T1 and T2 images for 
each well, while the normalized CDR or CDR% of each well calculated by taking 




where CDRpos and CDRneg are the average CDR values of the negative and 
positive control wells respectively in each test plate (Inglese, Shamu et al. 2007). 
 
EMT time-lapse video 
EMT inhibitory effects of selected compounds were validated by NBT-II 
epithelial colony time-lapse videoscopy. NBT-II cells were plated onto a 12-well 
plate (BD) at a low density of 2000 cells per well in 1 ml of assay medium. Cells 
were allowed to grow and form epithelial colonies for a period of 4 days. The 
cultures were then refreshed with assay medium containing growth factor (EGF or 
HGF) prior to video imaging. Video imaging of individual cell colonies was 
performed using a video microscope incubator system (Axiovert-200M, Carl 
Zeiss). Time-lapse images were taken at 5 min intervals for 18 hours. Tracking of 




Cells were lysed with protease/phosphatase inhibitor (Calbiochem) -containing 
RIPA buffer (Sigma). Proteins were separated in 8% polyacrylamide gels and 
transferred to PVDF membranes (Millipore). Membranes were blocked in 5% 
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BSA (Sigma) and incubated at 4
o
C overnight with MMP-13 (Millipore), E-
cadherin (BD), α-tubulin (Sigma) and pSmad2 245/250, pSmad2 467, Smad4, 
Smad3, pc-MET, c-MET, pEGFR, EGFR, pIGFR-1, IGFR-1, pERK 1/2, ERK 
(Cell Signaling) primary antibodies. Membranes were then developed with HRP-
conjugated secondary antibody (Amersham) and ECL substrate (Millipore). The 
blots were scanned using G:BOX Chemi XT16 (Syngene). 
 
Bladder cancer animal models 
Orthotopic model 
All animal work adhered to the Agency of Science Technology and Research 
(A*STAR), Institutional Animal Care and use Committee (IACUC), guidelines 
on animal use and handling. 6 to 8 weeks old female balb/c nude (nu/nu) mice 
were used.  General anesthesia was induced in the mice with inhaled isoflurane 
(4% for induction, 1-2% for maintenance) and maintained via nosecone.  Sterile 
ophthalmic ointment is applied to the animal’s eyes and a heating platform is used 
to maintain body heat. The urine of the animals was removed by applying gentle 
pressure on the bladder. Using a lubricated 24-guage intravenous catheter (Braun) 
connected to a 1ml syringe (BD) with the needle stylet removed, the mouse 
urethra was catheterized. A pair of forceps was used to gently lift the vulvar folds. 
A 45 degree angle was initially adopted to cannulate the urethra following which 
a shallower angle was taken to pass the catheter through the urethra into the 
bladder. Care was taken not to perforate the urethra or bladder. 100ul of PBS was 
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instilled into the bladder to wash the lumen. 100ul 0.2% Trypsin was instilled in 
the lumen for a maximum of 30 minutes. Following which the bladder was 
washed three times with 100ul PBS. 100ul of a 5x10^6 UMUC3-Luc2 cells was 
instilled into the bladder and the catheter and syringe left in place. The mouse was 
maintained under general anesthesia for 3 hours before the catheter and syringe 
was removed.  
Subcutaneous model 
Xenografts were generated by injecting 0.1ml of 2.5x10^6 of UMUC3-Luc cells 
subcutaneously into the dorsal flanks of female BALB/c nude mice (6 to 8 weeks 
old). Animal body weight and physical signs were monitored during the 
experiments. Tumour size was measured weekly by vernier caliper. The tumour 
volume was calculated, with the formula: [length x width2]/2. 
 
Bioluminescent Imaging 
General anesthesia was induced in mice with vaporized isoflurane and maintained 
via nose cone. Bioluminescence imaging was performed using the IVIS Spectrum 
Imaging System 200 (Xenogen) 10 minutes after an intraperitoneal injection of 
150mg/kg firefly D-Luciferin in 200uL of PBS. A digital grayscale image was 
acquired followed by an acquisition and overlay of a pseudocolor image 
representing the spatial distribution of detected photons emerging from active 
luciferase within the mouse. Signal intensity was quantified in photons per second 
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4% paraformaldehyde was delivered via a catheter into the mouse bladder lumen 
and was retained for 10 minutes. Following which the mouse urethra was tied and 
the whole bladder was excised and placed into 4% paraformaldehyde overnight at 
4
o
C.  The fixed bladder was paraffin embedded and paraffin blocks were cut at 
6um thickness per tissue section. Bladder tumours were deparaffinized before 
hematoxylin and eosin (H&E) staining. 
 
Colony formation assay 
The soft agar assay consisted of 3 layers. 0.6ml bottom layer of 0.6% agar in 
RPMI (Gibco, Life Technologies) supplemented with 10% fetal bovine serum 
(FBS, HyClone Thermo Scientific), was dispensed into each well of a 24-well 
plate and allowed to solidify at room temperature. The middle layer (0.5ml) 
consisted of 0.36% agar with UM-UC3 carcinoma cells in RPMI medium 
supplemented with 10% fetal bovine serum was plated above the bottom layer and 
allowed to solidify at room temperature. The top layer consisted of 0.5ml/well of 
RPMI medium supplemented with 10% fetal bovine serum and compounds. 
Experiments were set up in triplicates and incubated at 37
o
C in a humidified 




Error bars in CDR dose response plots in the EMT inhibition screen represent 
standard deviation of replicate samples. CDR IC50 values were calculated through 
sigmoidal curve fitting of CDR dose response plots using GraphPad Prism 
software. Statistical tests used are described in the individual figure legends. 
Prism (GraphPad Inc.) and Excel (Microsoft) softwares were used for calculations 










Chapter 3: Results 
Part 1: Progression scheme of high grade superficial tumours to 
the muscle invasive state in bladder cancer.  
Introduction 
 
Neoplastic transformation of urothelial cells gives rise to urothelial carcinomas 
broadly classified into non-muscle invasive (Ta and T1) and muscle invasive (> 
T2). Patients diagnosed with bladder carcinoma often suffer from recurrent 
tumours. At present, the mechanism leading to bladder cancer is still poorly 
understood and our knowledge about progression from low stage/grade to high 
stage/grade tumours is also limited. Much effort has been made to understand the 
etiology of bladder cancer and it has revealed that urothelial carcinoma develops 
through a multistep process, accumulating genetic alterations during progression.  
Non-muscle invasive tumours are difficult to eradicate and have diverse 
prognosis. Low grade Ta tumours rarely progress to muscle invasive tumours but 
frequently recur while high grade Ta and T1 tumours display a higher risk of 
progression. Tumours progressing to muscle invasive carcinomas are life 
threatening as these tumours often lead to extensive metastasis. These 
observations prompt to identify molecular mechanisms that govern the 
progression of high grade tumours in order to treat patients with a more specific 
therapeutic regimen.    
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EMT is an important process in high grade bladder tumours. It is characterized by 
a down-regulation of the E-cadherin adhesion molecule and of proteins associated 
with cell polarity along with up regulation of fibronectin, vimentin and MMPs. 
EMT induced by TGF-β and growth factors such EGF family members and HGF 
is associated with loss of differentiation and increased migration, invasion and 
angiogenesis.  Dissecting the EMT process into functional modules might provide 
an insight to a better understanding of the progression of high grade tumours.  
In order to study the events leading to cancer cell dissemination, we have chosen 
to study an in vitro bladder cancer cell model which exhibits a transition from 
bona fide epithelial, forming cobblestone colonies to migratory single 
mesenchymal cells. The cell line model designated Nara Bladder Tumour-II 
(NBT-II) carcinoma cell line was established from a rat bladder carcinoma. 
Wistar rats were given the carcinogen, BBN(N-butyl-N-(4-hydroxybutyl) 
nitrosamine) at a concentration of 0.05% in drinking water for 20 weeks  to 
induce bladder tumours (Toyoshima, Ito et al. 1971). The tumours produced by 
this carcinogen resemble invasive human bladder cancer in histology, etiology 
and in kinetics. Bladder tumours in rodents are often Tis and were of high grade 
with invasive potential. NBT-II carcinoma cells present a favourable model to 
work with for in vitro studies. NBT-II cells can undergo EMT in response to 
several different growth factors and extracellular matrix proteins (Valles, Boyer et 
al. 1990); (Tucker, Boyer et al. 1991); (Bellusci, Moens et al. 1994); (Petit, Boyer 
et al. 2000) 
46 
 
The oligonucleotide microarray technology offers the possibility to quantify 
expression levels of thousands of genes in parallel. DNA microarray analysis has 
emerged as an important tool to identify genes that are differentially expressed in 
normal and disease state. An in-depth analysis of microarray expression profiling 
can provide 1) association studies which aim to construct a panel of genes or 
biological pathways implicated, 2) class discovery which aims to discover clusters 
based on molecular data and 3) prediction studies which aims to classify patients 
based on clinical endpoints and drug response. In our study, DNA microarray 
technology is utilised to dissect step by step the EMT process enabling the 
discovery of step-wise activation of biological pathways critical in the progression 




NBT-II carcinoma cells undergo EMT in response to EGF and HGF.  
NBT-II cells treated with epidermal growth factor (EGF) or hepatocyte growth 
factor (HGF) for 24 hours undergone EMT. The edge of untreated colonies was 
well defined with cells displaying an epithelial morphology and retaining cell-cell 
contacts; while the edge of colonies treated with EGF or HGF was disrupted with 
cells acquiring a mesenchymal morphology accompanied by the loss of cell-cell 





Figure 5: EGF or HGF disrupts cell-cell contacts and induce morphological 
changes in NBT-II cells. 
NBT-II cells (5000 cells per well/96 well-plate) were seeded onto the center of each 
well to compact for 5 hours before incubation with growth factors (20ng/ml EGF, 
5ng/ml HGF) for 24 hours. Colony: phase contrast pictures taken at 4x magnification; 
Colony edge: phase contrast pictures taken at 10x magnification. 
 
 
Desmoplakin redistributed from the membrane cortex to the cytoplasm, indicating 
loss of cell-cell contact; and Vimentin increased after 24 hours of EGF or HGF 
treatment, indicating EMT (Figure 6A). To assess motility, NBT-II cells were 
tracked for 18 hours using time-lapse microscopy. As seen in Figure 6B, NBT-II 
cells treated with EGF and HGF travelled significantly further (EGF: 764µm, 
HGF: 634 µm vs Ctrl: 203 µm) with an increase velocity (EGF: 60 µm/hr, HGF: 







Figure 6: EGF and HGF induce MT in NBT-II cells. 
(A) NBT-II carcinoma cells were grown for 4 days to form cell colonies before the 
start of experiment. Cell colonies were then treated with HGF (5ng/ml) or EGF 
(20ng/ml) for 24 hours. Top panel, Green: Desmoplakin (cell-cell contact); Third 
panel, Green: Vimentin (intermediate filament); Red: H2b (nuclear stain). Images are 
representative of 3 independent experiments. (B) illustrates the individual tracks of 30 
cells in the colony.  (C) and (D) show an increase in velocity and distance travelled by 
NBT-II cells treated with EGF/HGF. Bars represent mean + SEM. *p<0.05 , two-tailed 








Gene expression profiling was performed on NBT-II cells treated for 24 hours 
with EGF and HGF to identify differential gene expression correlating with that 
of the morphological and behavioural changes induced by growth factor in NBT-
II cells.  Transcriptome analysis provided a list of 383 genes regulated by both 
EGF and HGF (Figure 7A). Among the genes that were regulated by EGF and 
HGF, transcriptome analysis also identified a subset of genes that were closely 
related to EMT. The expression of these genes was validated using quantitative 
reverse transcription polymerase chain reaction (qRT-PCR). An up-regulation of 
mesenchymal markers such as Matrix metalloproteinase 3 (Mmp3), Serpin 
peptidase inhibitor, clade e, member1 (Serpine1) and Zinc finger E-box binding 
homeobox 1 (Zeb1) and a down-regulation of epithelial markers such as 
Desmoplakin (Dsp), Keratin 19 (Krt 19) and Occludin (Ocln) was observed 
(Figure 7B). Taken together, the data demonstrated that NBT-II cells can undergo 
morphological and behavioural changes characteristic of epithelial mesenchymal 





Figure 7: Transcriptomic analysis revealed common genes induced or repressed 
by EGF and HGF.  
(A) The differential expression level for each of the growth factor (E/H) treated 
samples is provided relative to the untreated (U) samples. A set of 383 common genes 
showed significant over-expression/down-regulation in the presence of EGF/HGF. E= 
EGF; H= HGF. Arrays were analysed in duplicates: white bar = repeat 1; black bar = 
repeat 2. (B) Further analysis of the 383 genes revealed a subset of EMT-related genes. 
Real-time PCR analysis with reverse transcription showing fold induction of Mmp3, 
Serpine1, Zeb1 and fold reduction of Dsp, Krt19 and Ocln messenger RNAs in NBT-II 
cells treated with EGF/HGF. Data are normalized with the expression levels of 
housekeeping genes and represent the mean of 3 independent experiments. Bars 






NBT-II carcinoma cells in response to EGF and HGF engage in processes 
relevant to tumour progression   
Gene ontology analysis revealed that the 383 genes participated in biological 
processes typical of tumour progression such as actin cytoskeleton organization, 
cell migration and cell proliferation (Table 1). Pathway analysis indicated focal 
adhesion, ECM-receptor interaction and ErbB signalling as the top three networks 
(Table 2). Genes of these networks regulate cell-substrate adhesion and affect the 
stability of cortical actin which are both important for EMT and migration. Up-
regulation of ErbB family ligands as well as v-myc myelocytomatosis viral 
oncogene homolog (Myc) and PI3K contribute to cell survival.  Moreover, down-
regulation of tumour suppressors like Grhl3, Gata3, Id4, Hoxd10 and Bhlhe40 
were observed among the 383 genes (Appendices). Taken together, the data 
demonstrated that under the influence of growth factors, NBT-II cells can 
recapitulate certain aspects of tumour progression. 





Table 2: Top 3 pathways in EGF/HGF induced NBT-II cells.  
 
 
NBT-II carcinoma cells induced by EGF and HGF express genes found in 
advanced stages of bladder cancer 
Since constitutively activated growth factor receptors and elevated serum levels of 
growth factors were causal factors for invasion and metastasis in cancer, the list of 
383 gene list was further explored by comparing it with 7 published human 
bladder cancer microarray data sets comprising 400 patients. This analysis 
identified a set of EGF/HGF driven genes (Table 3) that were deregulated in 
invasive bladder cancer. This further affirms the role EGF and HGF play in 






Table 3: Identification of a subset of genes implicated in invasive bladder cancer.  
 
Changes in cell morphology and motility observed post HGF induction 
Muscle-invasive bladder cancer patients have higher serum levels of HGF than 
patients with superficial ones. To address the impact of HGF signalling on 
bladder cancer progression, subsequent studies will focus on the contribution of 
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HGF to the changes in cell morphology, motility and differential gene 
expressions. To investigate the dynamic changes in phenotype during HGF-
induced mesenchymal transition, images of NBT-II carcinoma cells were taken at 
an interval of 5 minutes for 48 hours and compiled into a movie using Axiovision 
software. Under the influence of HGF treatment, coherent sheets of epithelial 
NBT-II carcinoma cells progressively dissociated, leading to single cells with 
increased spreading and lamellipodial activity. The time-points were recorded 
when an observable change in morphology and behaviour of NBT-II carcinoma 
cells was detected. NBT-II carcinoma cells remained in the epithelial state after 2 
hours of HGF treatment and engaged into locomotion within 3-4 hours following 
HGF induction. 4 hours post HGF treatment, NBT-II carcinoma cells enter a 
meta-stable state in which epithelial colonies were disrupted and each cell can 
alternatively remain stationary or locomote; and 9 hours post HGF induction, 
NBT-II carcinoma cells reached a mesenchymal state in which the scatter effect 
was preeminent and NBT-II carcinoma cells migrated out of the colonized area 
(Figure 8A). To assess motility for the 6 defined time-points (0, 2, 4, 6, 9, 24 
hours), NBT-II carcinoma cells were tracked for an hour at each time-point using 
timelapse microscopy. NBT-II carcinoma cells that entered the meta-stable state 
migrated with a 2-fold increase in velocity as compared to cells in the epithelial 
state (Figure 8C). NBT-II cells in the EMT-ed state travelled significantly further 
(Figure 8D) with an increase velocity (Figure 8C) that resulted in larger total 






Figure 8: HGF induced subsequent changes in cell morphology and cell 
migration. 
(A) NBT-II carcinoma cells were grown for 4 days to form cell colonies. The cell 
colonies were subsequently treated with HGF (5ng/ml) and imaged at 2, 4, 6, 9, 24 
hours post HGF. (B) illustrates the individual tracks of 8 cells in the colony.  (C), (D) 
and (E) show an increase in velocity, distance travelled and displacement of NBT-II 





C D E 
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Sets of genes with sustained expression shift NBT-II cells towards a more 
invasive state 
In an attempt to investigate how cancer cells shift towards a more malignant state 
under the influence of a growth factor, gene expression profiling was performed 
on NBT-II cells treated with HGF for the 6 defined time-points. Gene scores were 
computed and 326 genes (226+76+24 numbers represented in red in Table 4) 
were observed with sustained expression over 3 or more time-points. Detailed 
analysis was performed on these 326 genes as these genes might provide clues to 
the mechanism of tumour progression. Pathway analysis indicated that ErbB, p53, 
MAPK signalling and focal adhesion related pathways were altered (Table5). 
Dysregulation of ErbB, MAPK and p53 pathways promote cell survival and 
apoptosis evasion (Witsch, Sela et al. 2010) (Plati, Bucur et al. 2008). Focal 
adhesion related pathway regulates cell motion and invasion processes 
(Huttenlocher and Horwitz 2011). Gene ontology analysis also revealed biological 
processes related to migration like regulation of cell motion (GO:0051270) and 
branching morphogenesis (GO:0049754) (Table 6).  For example, genes up-
regulated in this analysis were often over-expressed in metastatic cancers. Down-
regulation of FGFR3 gene expression was also observed in the microarray 
analysis. Down regulation of FGFR3 together with alteration of p53 pathway 
suggested that NBT-II carcinoma cells under the influence of HGF shifted 
towards a pro-invasive state, consistent with the current bladder cancer findings in 
which tumours switch from Ta or T1 stages to invasive stages with a shift in 
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FGFR3 and p53 status (Neuzillet, Paoletti et al. 2012) (van Rhijn, van der Kwast 
et al. 2004).    
   
Table 4: Gene Score: the frequency of a gene detected over 6 time-points  
FDR, Fc                   score 1 2 3 4 5 6 
0.05, 1.5 660 325 226 76 24 0 
 
Score 1: gene appear once in the 6 time-points 
Score 2: gene appear twice in the 6 time-points 
Score 3: gene appear 3 times in the 6 time-points 
Score 4: gene appear 4 times in the 6 time-points 
Score 5: gene appear 5 times in the 6 time-points 
Score 6: gene appear in all 6 time-points  
For example, 660 genes with score 1 means 660 genes are detected once in the 6 
time-points studied. 
FDR: false discovery rate 














Expression profiles reveal sets of genes at different time-points, sequentially 
contributing to malignancy 
To delve deeper, detailed analysis was performed on genes that were differentially 
expressed at each time-point. Analysis indicated that the dominating signalling 
pathway was MAPK at 2 hours post HGF treatment, followed by ErbB and TGFb 
signalling pathways (Table 7). Genes that regulate adherens junctions and tight 
junctions (Claudin 4 (Cldn4), Actinin, alpha 1 (Actn1), Tight junction protein 2 
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(Tjp2)) were affected, suggesting NBT-II carcinoma cells were prone to undergo 
dissociation.  








Cells at the meta-stable state showed the greatest number of differentially 
expressed genes with 419 and 449 genes observed at 4 and 6 hours post HGF 
treatment respectively (Figure 9). In addition to the 3 pathways mentioned above, 
6 other pathways:  p53, Neurotrophin, VEGF, Insulin, chemokine and Jak-Stat 
signalling pathways emerged at 4 hours post HGF treatment. At 6 hours post HGF 
treatment, TGFβ signalling was not detected by the analysis and instead 
Phosphatidylinositol signalling pathway was observed.  More genes were 
observed for regulating focal adhesion, cell cycle, junctional complexes, axon 
guidance and endocytosis. Genes that regulated B cell receptor and Natural killer 
cell signalling were also observed. At 24 hours post HGF treatment, ErbB, p53, 
phosphatidylinositol and TGFβ signalling pathways were detected. The 
emergence of TGFβ signalling pathway at 24 hours might indicate a switch in its 
tumour suppressor role to one that promotes tumour progression.  Genes that 
regulate focal adhesion formation and actin cytoskeleton reorganization were 
dominant throughout 6-24 hours post HGF treatment.  
 
 
Figure 9: Number of differentially 
expressed genes at each time-point. 
Total number of differentially 
expressed genes was determined for 
each time-point peaking at 6 hours post 




To investigate if the pathways detected 2 hours post HGF were essential in the 
acquisition of the mesenchymal state, we compared NBT-II carcinoma cell colony 
dispersion by vehicle and targeted inhibitors (Table 8). 
 
Table 8: Inhibitors used for drug treatment colony dispersion assay 
c-Met inhibitor EGFR inhibitor MEK inhibitor TGFβRI inhibitor 





We utilised the colony dispersion phenotype as readout since cell dissociation is 
the first step in the acquisition of a mesenchymal phenotype. Under normal 
growth conditions, NBT-II carcinoma cells grew to form an epithelial cell colony 
but with addition of HGF, NBT-II carcinoma cells acquired mesenchymal 
features and dispersed from the colony. In the presence of HGF, NBT-II 
carcinoma cells were treated with inhibitors of EGFR, MEK and TGFβRI and 
assessed if cell colonies remained intact or dispersed.  
NBT-II carcinoma cells were induced by HGF and c-Met inhibitor was used as a 
positive control (intact cell colony).  Colonies remained intact when cells were 
pre-treated with c-Met inhibitors overnight before addition of HGF. NBT-II cell 
colonies dispersed in the presence of EGFR inhibitor under HGF induction 
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(Figure 10) even though ErbB signalling was detected by the analysis. Colonies 
remained intact when cells were treated with MEK or TGFβRI inhibitor overnight 
before addition of HGF (Figure 11).  
 
 
Figure 10: EGFR 





 NBT-II carcinoma 
cells were seeded onto 
each well center of 96 
well-plates to form cell 
colonies for 4 hours 
before the start of 
experiment. Cell colonies 
were then treated 
overnight with DMSO 
(drug vehicle), 5µM 
PD153035 (EGFR 
inhibitor) or 4µm 
JNJ38877605 (c-Met 
inhibitor) before the 
addition of HGF (5ng/ml). 
Phase contrast images are 





Next, instead of incubating cells with inhibitors before the addition of HGF, 
inhibitors were added to the culture 0.5, 2 and 5 hours after the addition of HGF 
to observe if the inhibitors were still able to abrogate the process of mesenchymal 
state acquisition. Colonies with the different treatment conditions were imaged 24 
hours post HGF treatment (Figure 11). We observed that colonies remained 
compact when the colonies were treated with c-Met, MEK or TGFβR inhibitors 
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0.5 and 2 hours after addition of HGF. Cells in colonies undergo partial dispersion 
if MEK or TGFβR inhibitors were added after 5 hours of exposure to HGF. If 
MAPK and TGF-β pathways were inhibited within 2 hours of exposure to HGF, 
EMT was abrogated. The data suggested that subsequent activation of MAPK and 
TGFβ signalling pathways are required for EMT; and these two signallling 
modules are early events in the HGF induced cascade. Early inhibition of each of 
the two pathways can abrogate the EMT process but if the EMT process has been 
engaged (post 5 hours of HGF induction), blocking either of the two pathways 





Figure11: Inhibition of HGF induced cell dispersion with targeted inhibitors of 
TGFβRI and MEK. 
NBT-II cells (100 cells per well) were plated for four days to allow for colony growth. 
No drug: NBT-II cells treated with DMSO (drug vehicle); Overnight drug: NBT-II 
cells were pre-treated overnight with inhibitors before addition of HGF; 0.5, 2, 5 hr 
post HGF: inhibitors were added 0.5 hour, 2 hours, 5 hours after the addition of HGF 
respectively. TGFbRI inhibitor: 10µM A83-01; MEK inhibitor: 2 µM PD0325901. 




MEK and TGFβRI act on a common downstream target 
The most relevant target to investigate is Smad2 as both ERK (direct target of 
MEK) and TGFβRI phosphorylates Smad2. Specifically, the linker region of 
Smad2 is phosphorylated by ERK whilst the C-terminus is phosphorylated by 
TGFβRI (Hough, Radu et al. 2012) (Heldin and Moustakas 2012). siRNA 
knockdown of Smad2 was performed to assess if Smad2 is implicated in the 
HGF-induced EMT process. Small interfering ribonucleic acid (siRNA) 
knockdown for Smad2 was successful, yielding greater than 80% decrease in total 
Smad2 protein level (Figure 12A). siRNA knockdown of Smad2 prevented the 
dispersion of the HGF treated cell colonies (Figure 12B) and delayed the HGF-
induced wound-closure (Figure 12E).  
Both Smad2 and Smad3 are activated by TGFβRI mediated C-terminal 
phosphorylation; thereafter forming complexes with Smad4 before translocating 
to the nucleus where they bind other transcription factors to regulate the 
transcription of specific genes.  Knockdown of Smad2-binding partners (Smad3 
and Smad4) was performed. However siRNA knockdown for Smad3 was 
unsuccessful, yielding less than 20% knockdown in protein level (Figure12C) 
while siRNA knockdown for Smad4 lead to greater than 80% decrease in protein 
expression (Figure 12F). The siRNA knockdown of Smad4 resulted in a delay in 
wound-closure compared to the control (Figure 12G).  
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Figure 12:  siRNA knockdown of Smad2 and Smad4 delayed HGF induced 
wound closure. 
(A)  Western blot analysis of protein levels of Smad2. (B) Colony dispersion assay of 
NBT-II cells transfected with Smad2 siRNA under HGF induction. (C) Western blot 
analysis of protein levels of Smad3 and Smad4 (F) after transfection with 50nM of 
their specific siRNA. A wound-healing assay was performed under HGF-treated 
conditions using NBT-II cells transfected with no siRNA (Control), negative siRNA, 
Smad2 siRNA (E) and Smad4 siRNA (G). Yellow lines mark the wound boundary. 
(D) Total Migration Area (TMA) is reduced in cells transfected with Smad2 siRNA 
and Smad4 siRNA. TMA is calculated by subtracting the area of the wound at 24hr 
from the area of wound at 0hr.  n.s= not significant.  Bars represent mean + SEM. 










In order to measure the area migrated by the cells, we subtracted the area of the 
wound at 24 hours from the area of the wound at 0 hour. The area occupied by 
migrated cells was significantly reduced when Smad2 or Smad4 (Figure 12D) 
were knockdown. These results further affirm the role of Smad2 in HGF-induced 
EMT and motility. 
Using immunofluorescence labelling, Smad2 localized in the nucleus of NBT-II 
carcinoma cells 2 hours after HGF induction (Figure 13A). This HGF-induced 
Smad2 nuclear localization was inhibited with the addition of A83-01 (TGFβRI 
inhibitor), suggesting that the translocation of Smad2 to the nucleus is TGFβRI 
dependent.  
Next, a fractionation assay was used to extract the cytoplasm and nuclear 
fractions from total cell lysates to study the level of phosphorylated Smad2 in 
each fraction for the different conditions.  The fractionation assay similarly 
showed an increase in C-terminal phosphorylated Smad2 in the nuclear fraction 2 
hours after the addition of HGF (Figure 13B). This increase was again inhibited 
with the addition of A83-01(TGFβRI inhibitor) which further affirmed that the 
translocation of Smad2 to the nucleus is TGFβRI dependent and TGFβRI 
mediated Smad2 C-terminal phosphorylation is critical for the translocation of 






Figure 13: Nuclear translocation of Smad2 upon HGF induction is dependent on 
Smad2 C-terminus phosphorylation. 
 (A) NBT-II carcinoma cells were grown for 4 days to form cell colonies before the 
start of experiment. Cell colonies were pre-treated overnight with Vehicle (DMSO) 
or 10µM A83-01 (TGFbRI inhibitor) before addition of HGF (5ng/ml). Cultures 
were fixed 2 hours post HGF addition and stained for Smad2 protein. Green: Smad2; 
Blue: Dapi (nuclear stain). (B) Fractionation assay: Smad2 was observed in the 
nuclear fraction 2 hours post HGF addition. n: Nuclear fraction; c: Cytoplasmic 




Smad2 is phosphorylated by ERK at the linker region and by TGFβRI at the C-
terminus; the phosphorylation dynamics of the two regions (linker and C-
terminus) of Smad2 might suggest how Smad2 is regulated. An increase in 
phosphorylation of the Smad2 linker region (Smad2 S245/S250/S255) was 
observed 0.5 hours after HGF induction, while an increase in the phosphorylation 
of Smad2 C-terminus (Smad2 S465/S467) was observed only 1 hour after HGF 
induction (Figure 14A). We hypothesized that the phosphorylation of Smad2 




phosphorylation of Smad2 C-terminus. The administration of PD0325901 (MEK 
inhibitor) inhibited the activation of its direct target, ERK, thereby abrogating the 
phosphorylation of Smad2 linker region (Figure 14B). However, abrogating the 
phosphorylation of Smad2 linker region resulted in an unexpected increase in the 
phosphorylation of the Smad2 C-terminus (Figure 14B), suggesting that the 
Smad2 linker phosphorylation might inhibit the phosphorylation of Smad2 C-
terminus.  
We also observed that a decrease in the pERK1/2 (phosphorylated ERK1/2) was 
accompanied by a decrease in the phosphorylation of the Smad2 linker region and 
an increase in the phosphorylation of the Smad2 C-terminus 1 hour after HGF 
induction (Figure 14A). This led to the conclusion that ERK1/2 may function like 
a switch to regulate the phosphorylation of Smad2 C-terminus via Smad2 linker 













A   
Figure 14: Phosphorylation of 
Smad2 linker region inhibits the 
phosphorylation of Smad2 C-
terminus. 
 
 (A) Top panel: Immunoblots for 
pSmad2 S250 (linker region 
S245/S250/S255), pErk1/2 displayed 
activation within 0.5 hour (lane 2) by 
HGF; pSmad2 S467 (C-terminus 
region S465/S467) activation at 
1hour (lane3) by HGF. Bottom panel: 
graph that display the fold-induction 
of phosphorylating pSmad2 S250 
(white), pERK1 (light grey), pERK2 
(dark grey) and pSmad2 S467 (black) 
compared to control (CTRL). The 
trend of pErk1/2 (Grey bars) is 
opposite to that of pSmad2 S467 
(black bars). Data represent the mean 
of two independent experiments. 
Bars represent mean + Standard 
Deviation. *= p-value < 0.05 when 
compared to control. 
 = p-value < 0.05 when 
compared to 0.5 hours after HGF 
induction.  
 = p-value < 0.05 when 
compared to 3 hours after HGF 
induction.  
(B) Immunoblots for pSmad2 S250, 
whose induction by HGF is inhibited 
by PD0325901 (MEK inhibitor); 
activation of pSmad2 S467 was 
inhibited by A83-01 (TGFβRI 
inhibitor) but augmented by 
PD0325901. Drug vehicle: DMSO. 
α-Tubulin acts as loading controls. 
Data represent the mean of three 
independent experiments. Bars 
represent mean + Standard deviation. 
*= p-value < 0.05 when compared to 
control. **= p-value <0.05 when 












To investigate the role of the two phosphorylated Smad2 regions (linker and C-
terminus) in the EMT process, human bladder carcinoma cells (UM-UC-3) were 
treated with either MEK inhibitor (PD0325901) or TGFβRI inhibitor (A83-01); 
and tested for the expression of EMT markers Snail-1, Zeb1 and Twist (Figure 
15). The addition of PD0325901 (MEK inhibitor) abrogated the phosphorylation 
of ERK1/2 resulting in a non-phosphorylated Smad2 linker region accompanied 
by a decrease in Snail-1 and Zeb1 protein levels (Figure 15A). Furthermore, the 
abrogation of the Smad2 linker phosphorylation was accompanied by an increase 
in the phosphorylation of the Smad2 C-terminus with an increase in Twist protein 
level (Figure 15A). To study if the increase in Twist was due to the increase in 
Smad2 C-terminus phosphorylation, we treated UM-UC-3 with A83-01 (TGFβRI 
inhibitor) and PD0325901 (MEK inhibitor) in combination. With the addition of 
A83-01, a decrease in Twist protein level was observed (Figure 15B). The data 
showed that phosphorylation of the linker region of Smad2 regulated Snail-1 and 







Figure 15: Regulation of EMT markers by Smad2 linker and C-terminus region. 
Human bladder carcinoma cells (UM-UC-3) were cultured with culture medium 
containing either drug vehicle (DMSO), 10µM A83-01 (TGFβRI inhibitor) or 2µM 
PD0325901 (MEK inhibitor) for 3 days. (A) Immunoblots of Zeb1 and Snail, whose 
expression is diminished with the abrogation of phosphorylation of pSmad2 S250 
(linker region S245/S250/S255) upon PD0325901 (MEK inhibitor) treatment; Twist 
expression is up-regulated with an increase in pSmad2 S467 (C-terminus region 
S465/S467) phosphorylation (lane3). (B) Immunoblot of Twist, whose protein level 
increases in the presence of PD0325901 and is diminished when cells are treated with 








To investigate if phosphorylation of the linker and c-terminus regions in Smad2 is 
required for tumour initiation and sustenance, the human UM-UC-3 bladder 
carcinoma cell line was transfected with a cDNA construct plasmid that 
harboured mutations to abrogate the phosphorylation of the Smad2 linker region 
(Smad2 dnL) or the Smad2 C-terminus region (Smad2 dnC). The stably 
transfected cells were subcutaneously injected into the flanks of nude mice and 
observed for tumour growth. Cells that harboured Smad2 dnL plasmid were rarely 
tumorigenic with tumour forming in only 1 out of 5 mice (Figure 16A). Cells that 
harboured Smad2 dnC plasmid were tumorigenic with tumours forming in all 
mice (Figure 16A). Tumour volume of tumours derived from Smad2 dnL 
transfected cells was not significantly different from the tumour volume of 
tumours derived from Smad2 dnC transefected cells. However, the growth rate of 
the tumours derived from Smad2 dnL or Smad2 dnC transfected cells was 
significantly slower than tumours that derived from empty vector transfected 
cells; thus resulting in significantly smaller tumours compared to the tumours 
derived from empty Vector L or empty Vector C respectively (Figure 16B). These 
data suggested that the phosphorylation of the Smad2 linker region is important 









Figure 16: Abrogation of the phosphorylation of the Smad2 linker region and C-
terminus region reduces tumorigenicity and tumour growth respectively. 
Four UM-UC-3 stable cell lines were generated by stably transfecting UM-UC-3 cell 
line with Smad2dnL (non-phosphorylating Smad2 linker region) or Smad2dnC (non-
phosphorylating Smad2 C-terminus region) plasmid or their respective empty vectors 
(Vector L or Vector C). Each stable cell line was subcutaneously injected into the 
dorsal flanks of female athymic mice to form tumours. (A) Top panel: Mice were 
subcutaneously injected with Vector L stable UM-UC-3 cells on the left flank and 
Smad2dnL stable UM-UC-3 cells on the right flank.(N=5) Bottom panel: Mice were 
subcutaneously injected with Vector C stable UM-UC-3 cells on the left flank and 
Smad2dnC stable UM-UC-3 cells on the right flank. (N=5, 1 died) Right panel: 
Incidence of tumour formation for each stable cell line was calculated. (B) tumour 
volume was closely followed for 31 days, measurements taken twice every week. (D) 
Mice were euthanized and tumours were extracted. Bars represent the mean and error 








This study identified common transcripts regulated by both EGF and HGF 
signalling. A subset of the identified common transcripts was reported to be 
involved in invasive stages of bladder cancer. A gene of particular interest is 
HMGA1 that belongs to the high-mobility group A (HMGA) protein family. 
HMGA1 is a non-histone chromatin factor and several studies demonstrated that 
HMGA proteins have a critical role in neoplastic transformation. In pancreatic 
cancer, HMGA1 is over-expressed in >90% of primary pancreatic cancer, with 
low level in early precursor lesions. Over-expression of HMGA proteins is 
associated with a highly malignant phenotype, representing a poor prognostic 
index. HMGA1 cooperates with different molecules for tumour progression. 
HMGA1 cooperates with K-RAS to induce migration and anchorage-independent 
growth in cells. HMGA1 induces the expression of COX-2 and cells become non-
tumorigenic in vivo when HMGA1 is repressed. HMGA1 inhibits p53-mediated 
mitochondrial apoptosis by disrupting the binding of p53 and Bcl-2 though 
physical interaction with Bcl-2. HMGA1 was also reported to enhance cellular 
reprogramming from a somatic cell to a fully pluripotent stem cell. Since some 
cancer cells are considered to exhibit stem cell properties, further studies are 
required to investigate if HMGA1 contribute to poorly differentiated, stem-like 
cancers.  
Through the differential gene expression profile from each step of the EMT 
process, we were able to unravel the chronological activation of signalling 
modules termed the c-Met kinetic signature. The data reported in this chapter 
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displayed the streamlined events in response to HGF for acquisition of 
invasiveness in carcinoma cells. Although most of the identified genes are already 
known to associate with cancer, the majority of them have not been reported as 
induced in TCC. Some of the gene families (for example, genes related to cell 
adhesion, cell proliferation and immune response) identified in this study were 
also reported in studies performed on pooled tumour samples that represent 
different stages and grades (Thykjaer, Workman et al. 2001).  The limitation of 
the study is the absence of cancer microenvironment which filters c-Met’s 
involvement in processes like angiogenesis –a potent contributor to metastasis.  
We have also shown that Smad2 acts as a common downstream target of both 
ERK and TGFβRI in the c-Met driven system to regulate the expression of EMT 
markers (Figure 17); and Smad2 linker region is important for tumorigenicity and 
Smad2 C-terminus is important in tumour growth. In addition, knocking down the 
Smad2 protein abrogates wound-closure, demonstrating the importance of Smad2 
in HGF-induced cell migration.  
In summary, this study provided insights into the stepwise dysregulation of 
pathways which might be useful for designing therapeutics against high grade 
tumours with invasive potential. Further analysis and modeling of the data 
generated in this study are likely to result in the development of more 
sophisticated models of receptor-initiated signal transduction, endocytosis, 
trafficking and regulation. Future application of this stepwise analysis model to 
interrogate other processes like angiogenesis, regulation of miRNAs in cancer 
77 
 
progression and stepwise acquisition of chemoresistance may reveal mechanisms 
of pathogenesis in these systems. This may help to understand the role of each 





Figure 17: Diagram of Smad2 regulation by MEK and TGFβRI under HGF-
induced conditions, regulating the expression of different EMT markers. 
Under HGF induced conditions, ERK1/2 phosphorylates Smad2 linker region 
regulating Snail1 and Zeb1 expression while TGFβRI phosphorylates Smad2 C-
terminus region regulating Twist1 expression. Both regions of Smad2 are important in 








Bladder cancer progression is characterized by a massive invasion of carcinoma 
cells in the different layers of the bladder wall. Bladder cancer patients are 
reported to have elevated serum level of growth factors, namely hepatocyte 
growth factor (HGF), epidermal growth factor (EGF), transforming growth factor-
beta (TGF-β) and insulin-like growth factor-1 (IGF-1), among others.  These 
inducing agents act synergistically to promote tumour progression. The 
surrounding stroma cells secrete an array of cytokines and growth factors that aid 
in the metastasis of the primary tumour. (Thiery and Sleeman 2006; Moustakas 
and Heldin 2007)   
Extensive efforts have been made in identifying agents that could affect 
carcinoma cell survival and proliferation. However as today progress has been 
slow. The classical treatment of bladder carcinoma recurrent superficial stages or 
high grade stage1 is still intravesical injection of Bacillus Calmette-Guerin an 
attenuated vaccine to boost non-specifically immune response. Mitomycin C is 
also often used as an anti-proliferative agent for these early stages. Different 
chemotherapeutic drugs are used in very advanced bladder cancers as adjuvant 
therapy following partial or radical cystectomy whenever possible. These agents 
include cis-platinum (cis-Pt) with or without 5FU mitomycin C. These agents can 
be used in combination with radiotherapy. Very advanced patients can also be 
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given gemcitabine and cis-Pt, M-VAC (methotrexate vinblastine doxorubicin cis-
Pt) or cis-Pt and paclitaxel or docetaxel (Amercican Cancer Society Webpage). 
Many clinical trials explore combination therapies, phototherapy and targeted 
therapy such as erlotinib, an EGFR kinase inhibitor, in addition to the use of 
conventional chemotherapeutics (Clinicaltrials.gov). The drugs aforementioned 
were initially identified for their anti-proliferative activity. However, bladder 
cancer progression is not only determined by the ability of carcinomas cells to 
proliferate but also their invasive potential. Drugs that can limit the invasive 
potential of carcinoma cells may be more useful in the treatment of muscle 
invasive bladder cancer patients to delay tumour progression. Thus there is a need 
to search for agents that can limit the invasive potential of carcinoma cells as to 
complement the anti-proliferative agents.  
Agents that inhibit EMT might aid in limiting the invasiveness of bladder 
carcinoma cells as EMT precedes invasion and metastasis. However, there are 
currently no available drugs that specifically inhibit EMT. In an attempt to 
identify such possible candidates, a library of kinase inhibitors was investigated 
for their effectiveness in inhibiting HGF, EGF and IGF-1 induced EMT. The 
kinase inhibitors were originally designed to combat oncogene addiction in 
carcinoma cells. Numerous carcinoma were found to over-express either wild-
type or mutated kinases (Lemmon and Schlessinger 2010)  (Schlessinger 2000) 
and these oncogenic kinases play important roles in sustaining tumour growth. 
Kinase inhibitors are selected for their ability to bind to the ATP-binding site of 
the dysregulated kinase thereby inhibiting phosphorylation and activation of the 
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signal transduction cascade responsible for sustaining tumour growth. Many 
preclinical studies showed the effectiveness of targeted small molecule inhibitors 
in limiting tumour growth. Examples include Gefitinib (EGFR inhibitor) for the 
treatment of non-small-cell lung cancer (Mok, Wu et al. 2009); and Imatinib 
Mesylate (PDGFR inhibitor) for the treatment of chronic myeloid leukemia 
(Hochhaus, Druker et al. 2008).  Although these inhibitors were identified and 
optimized for their anti-proliferative properties, evidence suggests that some of 
these targeted small molecule inhibitors may also interfere with EMT; since the 
EMT program is governed by signalling pathways for which these small 
molecular weight compounds have been generated (Thiery and Sleeman 2006) 
(Chua, Poon et al. 2011). For example, Ki26894, an ALK5 inhibitor, has been 
shown to decrease the invasiveness and EMT of scirrhous gastric cancer cells 
(Shinto, Yashiro et al. 2010). Therefore, screening a library of kinase inhibitors 
might aid in the identification of possible candidates that can reduce the invasive 
potential of bladder carcinoma cells. 
An EMT inhibition drug screening assay to identify EMT inhibitors was designed 
and developed in collaboration with Dr. Chua Kian Ngiap from assay 
development team of Experimental Therapeutics Center, A*STAR and the image 
analysis algorithm was developed by Dr. Victor Racine. This assay uses a model 
carcinoma reporter cell line (NBT-II) which was induced to undergo EMT 
initiated by different growth factors: EGF, HGF, or IGF-1. The inhibitors were 
screened for their EMT modulating properties through inhibition of growth factor 





The design and assembly of EMT inhibition drug screening assay. 
EMT inhibitory compound screen utilises a spot migration assay which measures 
the dispersion of cells in the presence of a test compound and an EMT inducer. 
H2B–mcherry transfected NBT-II stable cell line established in the lab was used 
for this assay. The red nuclei of the cells enabled the tracking of individual cell 
via live-cell fluorescent imaging.   The cells were plated onto the center of each 
96 well of clear bottom assay plates using a robotic liquid handling station at a 
concentration of 5million cells/ml. The cells were allowed to adhere for an hour 
before addition of more media to allow the cells to form a colony over 4-6 hour 
incubation period. The cells were then incubated overnight with low molecular 
weight compounds and subsequently treated with growth factor for 24 hours 
(Figure 18A). If cells remain epithelial and the colony is still intact after growth 
factor treatment, the tested compound is EMT inhibitory (Figure 18C).  
5 test compounds were screened on each assay plate in the plate layout as shown 
in Figure 18B. Each assay plate had a column of positive and negative control for 
comparison. The column of negative control wells were treated with a growth 
factor (HGF/EGF/IGF) following the treatment of DMSO. The positive control 
columns were treated with a growth factor (HGF/EGF/IGF) following the 
treatment of their respective receptor’s inhibitory compound that could inhibit the 
scatter function of that growth factor. For example, the c-Met inhibitor 
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(JNJ38877605) and the growth factor HGF; the EGFR inhibitor (AG1478) and the 
growth factor EGF; or the IGFR inhibitor (BMS536924) and the growth factor 
IGF. Images of the cell colony in each well were acquired prior to compound 
treatment, T1, and 24 hours after growth factor induction, T2, using a confocal 
microplate imager for comparison. The images obtained from T1 and T2 were 
sent for image analysis.  
The effect of the test compounds were reported based on two parameters, cell 
count and cell dispersion (Figure 18D). The H2B-mcherry coloured cell nuclei 
were segmented using a wavelet decomposition scheme to remove 
inhomogeneous background and noise. A watershed procedure was then 
performed to redefine the boundary of any nuclei that failed to be separated by 
wavelet algorithm. All segmented nuclei with size that fell below the average size 
of all nuclei were removed from the analysis. The “cell count” of each well was 
computed by summing the total number of the segmented nuclei. The cell count 
ratio was calculated by taking cell count of T2/T1 of each well. The cell count 
ratio provided information on the proliferative status of the cell colony in response 
to the test compound. The cell count ratio of an analysed well below the threshold 
(proliferative index of 1.5) suggests that the test compound is cytotoxic and hence 
will be eliminated from the list. The “cell dispersion” of each colony is calculated 
by taking the standard deviation of the positions of all the cell nuclei with respect 






Figure 18: EMT spot migration screening assay overview. 
(A) Screening assay workflow. Robot-assisted plating of H2B-mcherry transfected 
NBT-II cells into the well centers of 96-well plates. The initial plate image acquired at 
T1 served as the baseline reference for calculating the cell count ratio and cell 
dispersion ratio values for each well. The cells were treated with test compounds 
overnight using the plate layout (B) and further incubated for 24 hours with a growth 
factor to induce EMT. Final plate image acquired at T2 depicted the dispersion 
response of cells 24 hours after addition of the test compounds and growth factor 
treatment.      (C) EMT can be initiated and maintained in epithelial cells via growth 
factor signalling. The prevention of cell dispersion directly correlates to the propensity 
of a test compound to block an induced EMT signalling pathway. (D) Nuclei 
segmentation, which consists of a wavelet transform and watershed algorithm steps, 
was applied to identify all nuclei in the well. The nuclei segmentation mask was then 
dilated to generate merging region areas where distinct cell clusters could be isolated. 
Nuclei within the colony of interest were measured. Cell count was determined by the 
total nuclei count within the colony. Cell dispersion was determined by applying the 







The X and Y coordinates of all cell nuclei were recorded and the average of the 
coordinates represented the center of the cell colony. The ratio of “cell dispersion” 
of T2/T1 corresponded to the scatter status of the cell colony. Cell dispersion ratio 
of an analysed well below the threshold (50%) suggests that the compound was 
successful in inhibiting the scatter.  
The threshold values for both parameters were established using Tocris kinase 
library as the reference. All plates were normalized to cell dispersion ratio 
[Positive control=0% and Negative control =100%] and cell count ratio [Positive 
control =2.4]. A threshold for cell count ratio was set at 1.5 and the threshold for 
cell dispersion ratio was set at 50% of Negative Control/Positive Control Cell 
dispersion ratios range. A compound yielding cell count ratio ≥ 1.5 and cell 
dispersion ratio ≤ 50% of NegCtrl / PosCtrl Cell Dispersion ratios range in both 




Figure 19: Cell dispersion ratio (CDR) vs. cell count ratio (CCR) plots.  
The graphs illustrate the behavior of NBT-II cells treated with different test compounds 
and growth factors in the spot migration assay. CDR threshold was set at 50% CDR 
between positive control CDR and negative control CDR. CCR threshold was set at 1.5 
growth rate. We assessed compounds that inhibit cell dispersion (less than CDR 
threshold) and do not severely inhibit cell growth (i.e. more than CCR threshold). To 
further refine our hits, the test compounds were run at a low and high concentration 
(1.67 and 6.67 mM, respectively). Hit compounds (crossed squares) were classified as 








Table: 9 CCR and CDR(%) readings for shortlisted compounds 
Peach- TGFβR inhibitors, Blue- MEK inhibitors, Purple- PI3K inhibitors,  
Green- Src inhibitors, White- respective receptor inhibitor 
 
Small molecular weight compounds that inhibited EMT induced by HGF, EGF, 
IGF-1 fall into 4 major classes of compounds.  
The EMT drug screen shortlisted 4 major classes of compounds that successfully 
inhibited the HGF, EGF and IGF induced scatter. The activity level of c-Met, 
EGFR and IGFR were taken into considerations to eliminate compounds with off-
target effects. To investigate if these shortlisted compounds affected the 
phosphorylation of the receptors, NBT-II carcinoma cells were pre-treated 
overnight with the shortlisted compounds (Table 9) and protein cell extracts were 
then collected after half hour treatment with HGF, EGF or IGF.  Lysates treated 
with the shortlisted compounds were blotted for the phosphorylation of c-Met, 
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EGFR and IGFR. NBTII lysates with no growth factor treatment displayed a low 
endogenous level of phosphorylation of the three receptors. The band intensity 
increased with addition of the ligand and diminished with the receptor-targeted 
inhibitor (Figure 20). 
A number of shortlisted compounds fall under the TGFβR class of compounds 
(Table 9 peach colour) and the shortlisted compounds were A83-01, D4476, 
LY364947, SB431542 and SD208.  The phosphorylation of EGFR and IGFR 
were not affected by all compounds tested while D4476, LY364947 and SD208 
abrogated the phosphorylation of c-Met; phosphorylation of c-Met was slightly 
augmented with A83-01 and slightly reduced with SB431542 treatment (Figure 
20). Those compounds which inhibited the phosphorylation of c-Met were 
removed from the list as they were considered non-specific; hence, A83-01 
compound was chosen to represent the TGFβR class of compounds for further 
validation.  
The next class of compounds (Table 9 blue) tested was targeted against MEK and 
the shortlisted compounds were AZD 6244, CI- 1040 and PD0325901. All 
compounds in this class did not affect the phosphorylation of c-Met and IGFR, 
however, AZD6244 and CI-1040 resulted a reduction in the phosphorylation of 
EGFR (Figure 21). PD0325901 was chosen to represent the Mek class of 




Figure 20: Several TGFβR targeted compounds affect the activity of c-Met, EGFR 
and IGFR.   
Top panel: Immunoblot for pcMet (phosphorylation of c-Met), whose phosphorylation 
increases with the addition of the ligand (HGF) and diminished with JNJ38877605 (a 
specific c-MET inhibitor). The ligand-induced phosphorylation of c-MET is inhibited 
by D4476, LY364947 and SD208; slight augmentation of c-Met phosphorylation by 
A83-01 and slight reduction in c-Met phosphorylation by SB431542. Middle panel: 
Immunoblot for pEGFR( phosphorylation of EGFR) whose phosphorylation increases 
with the addition of the ligand (EGF) and diminished with AG1478 (a specific EGFR 
inhibitor).  The ligand-induced phosphorylation of EGFR is not affected by the test 
compounds. Bottom panel: Immunoblot for pIGFR (phosphorylation of IGFR), whose 
phosphorylation increases with the addition of the ligand (IGF-1) and diminished with 
BMS-536924 (a specific IGFR inhibitor). IGF-1-induced IGFR phosphorylation is not 





Figure 21: 2 MEK targeted compounds affect the activity of EGFR but not c-Met 
and IGFR.   
Top panel: Immunoblot for pcMet (phosphorylation of c-Met), whose phosphorylation 
increases with the addition of the ligand (HGF) and diminished with JNJ38877605 (a 
specific c-Met inhibitor). MEK inhibitors do not affect the ligand induced 
phosphorylation of c-Met. Middle panel: Immunoblot for pEGFR(phosphorylation of 
EGFR) whose phosphorylation increases with the addition of the ligand (EGF) and 
diminished with AG1478 (a specific EGFR inhibitor).  The ligand induced 
phosphorylation of EGFR is inhibited by AZD6244 and CI-1040. Bottom panel: 
Immunoblot for pIGFR (phosphorylation of IGFR), whose phosphorylation increases 
with the addition of the ligand (IGF-1) and diminished with BMS-536924 (a specific 
IGFR inhibitor). IGF-1 induced IGFR phosphorylation is not affected by the test 





The third class of compounds (Table 9 purple) tested were inhibitors of PI3K 
namely, API-2, GDC0941, PI103, PIK90 and ZSTK474. All compounds in this 
class caused an increase in phosphorylation of EGFR and IGFR; while API-2 and 
PI103 caused a reduction in ligand-induced c-Met phosphorylation (Figure 22). 
GDC0941 was chosen to represent the PI3K targeted class of compounds for 
further validation as GDC0941 presented lower cell dispersion ratios compared to 
PIK90 and ZSTK474 (Table 9).  
The fourth class of shortlisted compounds (Table 9 green) consisted of Src 
inhibitors (AZD0530 and PP1).  Both Src inhibitors, AZD0530 and PP1, caused a 
reduction in c-Met phosphorylation (Figure 23), suggesting the importance of an 
active Src protein in the maintenance of c-Met activity. The observations were 
similar to a report (Emaduddin, Bicknell et al. 2008) which showed a reduction in 
phosphorylation of Y1234/1235 c-Met by PP2, a pan SFK inhibitor. IGFR 
phosphorylation was not affected by the two compounds while PP1 interfered 
with the phosphorylation of EGFR. Therefore, AZD0530 was chosen to represent 




Figure 22: 2 PI3K targeted compounds caused a reduction in phosphorylation of 
c-Met, while augmenting EGFR and IGFR phosphorylation.   
Top panel: Immunoblot for pcMet (phosphorylation of c-Met), whose phosphorylation 
increases with the addition of the ligand (HGF) and diminished with JNJ38877605 (a 
specific c-MET inhibitor). The ligand induced phosphorylation of c-MET is inhibited 
by API-2 and PI103. Middle panel: Immunoblot for pEGFR( phosphorylation of 
EGFR) whose phosphorylation increases with the addition of the ligand (EGF) and 
diminished with AG1478 (a specific EGFR inhibitor).  The ligand induced 
phosphorylation of EGFR is not affected by the test compounds. Bottom panel: 
Immunoblot for pIGFR (phosphorylation of IGFR), whose phosphorylation increases 
with the addition of the ligand (IGF-1) and diminished with BMS-536924 (a specific 
IGFR inhibitor). IGF-1 induced IGFR phosphorylation is not affected by the tested 





Figure 23: Both Src targeted compounds affect the activity of c-Met.   
Top panel: Immunoblot for pcMet (phosphorylation of c-Met), whose phosphorylation 
increases with the addition of the ligand (HGF) and diminished with JNJ38877605 (a 
specific c-MET inhibitor). The ligand induced phosphorylation of c-MET is inhibited 
by both SRC inhibitors: AZD0530 and PP1. Middle panel: Immunoblot for pEGFR 
(phosphorylation of EGFR) whose phosphorylation increased with the addition of the 
ligand (EGF) and diminished with AG1478 (a specific EGFR inhibitor).  The ligand 
induced phosphorylation of EGFR is inhibited by PP1. Bottom panel: Immunoblot for 
pIGFR (phosphorylation of IGFR), whose phosphorylation increases with the addition 
of the ligand (IGF-1) and diminished with BMS-536924 (a specific IGFR inhibitor). 
IGF-1 induced IGFR phosphorylation is not affected by the test compounds. α-Tubulin 




The shortlisted representative compound from each class of inhibitors was tested 
for its relative potency in inhibiting growth factor induced EMT. We utilised the 
spot migration assay to measure the effectiveness of the shortlisted compound in 
inhibiting growth factor induced dispersion by determining the half maximal 
inhibitory concentration (IC50). The four shortlisted compounds have IC50 in the 
nanomolar range (A83-01: 130nM, PD0325901: 20nM, GDC0941: 380nM and 
AZD0530: 510 nM) for HGF induced EMT; (A83-01: 69nM, PD0325901: 31nM, 
GDC0941: 740nM and AZD0530: 560 nM) for EGF induced EMT and (A83-01: 
120nM, PD0325901: 8.9nM, GDC0941: 500nM and AZD0530: 240 nM) for IGF-





Figure 24: Relative propensity of the shortlisted compounds in inhibiting growth 
factor-induced dispersion. 
Top panel: Structure of short-listed small molecular weight compounds; from left to 
right: A83-01 (TGFβRI inhibitor), PD 0325901 (MEK inhibitor), GDC 0941 (PI3K 
inhibitor) and AZD 0530 (Src inhibitor). Second to Fourth panel: Graphs were plotted 
Cell Dispersion Ratio (Y-axis) against log µM (X-axis). Graphs display the dose 
response curve of compounds in inhibiting growth factor induced dispersion.   Second 
panel: Dose response curve to determine IC50 of short-listed compound in inhibiting 
EGF induced cell dispersion; from left to right: A83-01, PD 0325901, GDC 0941 and 
AZD 0530. Third panel: Dose response curve to determine IC50 of short-listed 
compound in inhibiting HGF-induced cell dispersion; from left to right: A83-01, PD 
0325901, GDC 0941 and AZD 0530. Fourth panel: Dose response curve to determine 
IC50 of short-listed compound in inhibiting HGF-induced cell dispersion; from left to 
right: A83-01, PD 0325901, GDC 0941 and AZD 0530. The four compounds inhibit 





4 representative compounds of each inhibitor class show EMT modulating 
properties 
NBT-II carcinoma cells were pre-treated with the representative compounds 
(A83-01, PD0325901, GDC0941, AZD0530) at 3 doses (0.5µM, 2µM, 8µM) 
overnight before induction by HGF, EGF or IGF-1 for 24 hours. Protein cell 
extracts were then blotted with antibodies against Mmp-13, a matrix 
metalloproteinase, and E-cadherin, the major adhesion molecule in adherens 
junctions. Mmp-13 is required for cell migration (Hattori, Mochizuki et al. 2009) 
and stromal expression of Mmp-13 contribute to invasion of carcinoma cells 
(Zigrino, Kuhn et al. 2009). Protein levels of Mmp-13 increased upon addition of 
HGF (Figure 25A), IGF-1 (Figure 25C) and modestly by EGF (Figure 25B). The 
IC50 AZD0530 (Src inhibitor) across all growth factors were approximately 
500nM and therefore a dose-dependent reduction of Mmp-13 protein levels by 
AZD0530 was observed under EGF, HGF and IGF-1 induction. A modest dose 
dependent reduction of Mmp-13 was also observed with TGFβRI inhibitor (A83-
01) under HGF and IGF-1 induction; the IC50 of this compound for both growth 
factors were approximately 100nM.  The IC50 of MEK inhibitor (PD0325901) 
across all growth factors was below 40nM and hence a complete reduction of 
Mmp-13 was observed for all growth factors. Each of the representative 
compounds of TGFβRI, Mek, PI3K and Src inhibitors were able to reduce Mmp-




Figure 25: Modulation of EMT markers, E-cadherin and MMP13, by shortlisted 
compounds.   
Immunoblot for MMP13 and E-cadherin, whose expression were modulated by EMT 
inhibitors under HGF (A), EGF (B), and IGF-1 (C) induced EMT conditions. E-
cadherin expression levels decreased with growth factor addition compared with 
DMSO control, indicating cells have undergone EMT. However, the E-cadherin level 
was restored or augmented with increasing compound concentrations, due to EMT 
inhibition effected by these compounds. Conversely, addition of HGF and IGF-1 
increased MMP-13 expression levels compared with DMSO control. In general, this 
increase in MMP-13 expression could be abrogated with the addition of the EMT 








These findings were consistent with previous reports showing that TGFβR, Src 
and Mek or its target, MAPK play a role in cell motility and tumour progression 
(Reddy, Nabha et al. 2003); (Wong, Chen et al. 2012); (Zhong, Chen et al. 2012).  
The 4 classes of compounds reduced the levels of Mmp-13, suggesting that these 
compounds lowered the cells potential in migration and invasion, consistent with 
the results of the screen. The cell lysates were then blotted for E-cadherin protein 
levels. All classes of compounds were able to augment the E-cadherin protein 
levels compared to growth factor treated ones. These results suggest that selective 
inhibition of MEK, PI3K, Src and TGFβRI could potentially revert EMT by 
restoring E-cadherin-mediated cell adhesion and reduce invasion through the 
inhibition of Mmp-13. . In addition, immunofluorescent labelling of 
Desmoplakins (epithelial marker) and Vimentin (mesenchymal marker) were 
included in the analyses to further confirm the EMT reversal induced by these 4 
classes of compounds. (Appendix 5,6)  
 
4 representative compounds reduced invasiveness of carcinoma cells. 
The shortlisted EMT inhibitory compounds were validated for their ability to 
reduce the invasiveness of cells induced by growth factor exposure using a 
Boyden chamber assay. NBT-II carcinoma cells were added to the top 
compartment while the growth factor (HGF, EGF or IGF-1) was added to the 
bottom compartment to allow NBT-II carcinoma cells to invade the matrigel in 
response to the growth factors. Each of the representative compounds was added 
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to the top compartment and tested for its effectiveness in reducing the invasive 
properties of growth factor induced NBT-II carcinoma cells.  
The traditional way of quantifying cells in this assay was to stain the cells with 
crystal violet dye and counting by eye under microscope. The traditional way is 
time consuming and prone to human error; therefore, we decided to stain the cells 
with Calcein AM and utilise a fluorometer for fluorescence quantification instead. 
To test whether quantification with fluorescence reading was acceptable in this 
assay, two independent transwell setups were done with identical conditions 
consisting of one control, one HGF-induced and one HGF+c-Met inhibitor (JNJ 
38877605). One set of the experiment was stained with crystal violet while the 
other set was stained with Calcein AM. The relative fluorescence reading was 
consistent with the pictures of crystal violet stained cells (Figure 26A) showing 
that the use of Calcein AM and its fluorescence reading was acceptable for this 
assay.  
The assay was extended to assess the ability of the 4 representative compounds to 
inhibit HGF, EGF or IGF-1 induced cell invasion. Greater number of NBT-II 
carcinoma cells under growth factor induction invaded the matrigel-coated insert 
compared to normal conditions (4.5 folds under HGF induction, 4.1 folds under 
EGF induction and 1.7 folds under IGF-1 induction) as shown in Figure 26B. 
Addition of the compounds (JNJ38877605 targeting c-Met, AG1478 targeting 
EGFR or BMS-536924 targeting IGF-1R) served as a positive control for each 
cognate receptors. Indeed, the addition of the positive control compounds 
decreased the number of cells that invaded the matrigel-coated inserts. All the 
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shortlisted compounds namely A83-01 targeting TGFβRI; PD0325901 targeting 
MEK; GDC0491 targeting PI3K; and AZD0530 targeting Src; successfully 
reduced the number of HGF, EGF or IGF-1-induced cells migrating through the 
matrigel-coated inserts (Figure 26B). Consistent with the screen, the shortlisted 
compounds were able to inhibit the in vitro matrigel invasion of growth factor 
induced NBT-II bladder carcinoma cells. 
 
 
Figure 26: Shortlisted compounds inhibit growth factor induced invasive 
capabilities in NBT-II bladder carcinoma cells.  
(A) No significant difference between the two detection methods used for quantifying 
cells that invaded through the matrigel-coated inserts in the boyden chamber assay. 
Left panel: Bright field images of crystal violet stained NBT-II cells that invaded 
through the matrigel-coated inserts.  Graph with Y-axis (Fluorescence reading) 
displays the values detected by the Tecan Infinite M100 Pro microplate reader when 





before reading. Greater number of cells invaded the matrigel-coated inserts with 
addition of HGF (about 4 fold increase compared to control). This invasiveness is 
inhibited by JNJ (JNJ 38877605), a specific compound for c-Met.  The graph with Y-
axis (Number of cells/field) displays the number of crystal violet stained NBT-II cells 
that invaded the matrigel-coated inserts, counted per field manually for each condition. 
The graph with Y-axis (Ratio of migrated cells) shows that there is no significant 
difference between the relative ratio calculated for the assay using Calcein AM 
fluorescence reading and assay using manual counting cells/field.  (B) The shortlisted 
compounds A83 (A83-01), a specific inhibitor for TGFβRI; PD (PD0325901), a 
specific inhibitor for MEK; GDC (GDC 0491), a specific inhibitor for PI3K; and AZD 
(AZD0530), a specific inhibitor of Src inhibit the HGF/EGF/IGF-1 induced in vitro 
matrigel invasion. Left: Graph displaying the relative ratio of cells that undergo HGF 
induced matrigel invasion; positive inhibitor control: JNJ. Middle: Graph displaying 
the relative ratio of cells that undergo EGF-induced matrigel invasion; positive 
inhibitor control: AG (AG1478), a specific inhibitor for EGFR. Right: Graph 
displaying the relative ratio of cells that undergo IGF-1 induced matrigel invasion; 




A TGFβRI EMT signature is found in c-Met driven EMT 
MEK, PI3K and Src are known downstream targets of growth factors; however 
the activation TGFβRI pathway has not been described in HGF, EGF and IGF 
signalling. Data from the drug screen concluded that TGFβRI inhibitor (A83-01) 
could inhibit growth factor induced EMT; hence an expression profiling was 
performed to uncover the TGFβRI EMT signature in this c-Met driven system. 
Under induction of HGF, the gene expression profile of TGFβRI inhibitor (A83-
01) treated cells was compared with Vehicle (DMSO) to identify genes affected 
by TGFβRI signalling under HGF induction. Two analyses were performed in 
order to identify the TGFβRI EMT signature in the c-Met driven system. The first 
analysis was to identify the genes regulated by HGF in which expression profile 
of cells treated with DMSO in absence of HGF was compared with that of cells 
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treated with DMSO and HGF. The second analysis was to compare profiling of 
DMSO+HGF versus A83-01+ HGF treated samples to identify the genes affected 
by the inhibition of TGFβRI. The overlap of the genes from the two analyses 
delivered 280 HGF-deregulated genes whose expression was reverted back to 
values comparable to control with TGFβRI inhibition. This list of 280 genes 
described the TGFβRI EMT signature under c-Met driven conditions (Figure 
27A). However, 177 genes failed to recover their gene expression towards the 
level at control state when A83-01 was added. In addition, Zeb1 was among the 
177 genes which expression was lowered but not 100% reverted by A83-01 
compound. This group of 177 genes was less efficiently regulated by TGFβ 
receptor than the group of 280 genes in the presence of HGF. Thus the TGFβRI 
EMT signature was defined by the 280 genes.  
To investigate the role of this TGFβRI EMT signature in HGF induction system, a 
gene ontology analysis on the 280 genes was performed with DAVID, a 
Functional Annotation Bioinformatics Microarray Analysis software provided 
free online by the National Institute of Allergy and Infectious Diseases (NIAID), 
at the National Institute of Health in Bethesda Md USA. The major pathways 
identified by the analysis were focal adhesion, ECM-receptor interaction and 
ErbB signalling (Table 10). Some of the 280 genes affected processes like cell 
motion, morphogenesis of branching structure, cell adhesion and actin 









Inhibition of TGFβRI reduced the expression level of Lamc2 also known as 
Laminin-5, Vcl (vinculin) and Itga2/3 (integrins) which are important players at 
focal adhesion sites. Laminin 5 induced cells to form large lamellae-like areas 
(Dogic, Rousselle et al. 1998) and NBT-II carcinoma cells when exposed to 
laminin-5 undergo locomotion.  Another gene identified critical for HGF induced 
cell migration was HB-EGF (heparin-binding EGF-like growth factor). The 
membrane bound HB-EGF was reported to regulate cell- matrix interactions while 
the soluble form increased HGF induced cell migration (Singh, Tsukada et al. 
2004). Inhibition of TGFβRI reduced the expression level of HB-EGF. A 
reduction of HB-EGF could perturb cell migration. In conclusion, A83-01 
compound showed certain EMT inhibiting features and the TGFβRI EMT 
signature governs the protein machinery for migration and invasion processes for 
















To further validate the microarray-based findings, 3 genes (Serpine1, p21 and 
Zyxin) were picked for analysis with western blot. Serpine1 also known as 
Plasminogen activator inhibitor-1 (PAI-1). PAI-1 was chosen for validation as it 
was identified as one of the gene transcripts in chapter one that contribute to 
tumour progression of bladder carcinoma cells; and it was found up-regulated in 
advanced stages of bladder cancer. Low concentration of PAI-1 was sufficient to 
modify the actin cytoskeleton and focal adhesions, promoting cell migration 
(Degryse, Neels et al. 2004).  The second gene validated was CDKN1a also 
known as cyclin-dependent kinase inhibitor 1 or CDK-interacting protein 1 
(p21/Cip1). p21 is a transcriptional target of the tumour suppressor gene, p53, and 
mediates the p53-dependent cell cycle G1 phase arrest (Abbas and Dutta 2009).  
Other than an effector of anti-proliferative signals, p21 can also display anti-
apoptotic effects through direct binding and inhibiting the transactivation activity 
of the transcription factors: E2F transcription factor 1 (E2F1), signal transducer 
and activator of transcription 3 (STAT3) and Myc. The third gene validated was 
Zyxin which is a zinc-binding phosphoprotein that concentrates at focal 
adhesions; and its proline rich N-terminal domain mediates actin polymerization. 
Zyxin may be a potential effector protein that contributes to locomotion by 
modulating the actin cytoskeletal organization. Protein levels of PAI-1, p21 and 
Zyxin were elevated under HGF induction and decreased upon A83-01 (TGFβRI 
inhibitor) addition. The protein level of PAI-1 protein was reduced by A83-01 to a 






Figure 27: The TGFβRI EMT signature in c-MET driven EMT. 
(A)  The unsupervised clustering of the mean intensities in the two repeats of each 
condition:1) DMSO (drug vehicle) without (GF) growth factor versus DMSO+HGF 
and 2) DMSO+HGF versus A83-01+HGF. The addition of A83-01 (TGFβRI inhibitor) 
reversed the effect of the growth factor (HGF) for a group of 280 genes; A83-01 failed 
to revert a group of 177 HGF driven genes back to control conditions; and 99 genes 
were the side-effects of the drug. (B) Western blot analysis of protein level of PAI-1, 
p21 and Zyxin in NBT-II carcinoma cells treated with or without 2.5uM of A83-01 in 
the presence of 5ng/ml of HGF for 24 hours. The addition of A83-01 reverted the HGF 
induced PAI-1 protein expression; and to a lesser extent, p21 and Zyxin. Intensity of 
each western blot band was measured and normalized against band intensity of α-
Tubulin for each sample; relative fold change for each protein was calculated by 
comparing protein band intensity of vehicle or A83-01 against control.  α-Tubulin was 
used as a loading control. Bars represent mean + standard deviation. N=3. *= p-value 





Part 3: Validation of a TGFβRI inhibitor using an orthotopic 




The goal standard for treatment of superficial stage transitional carcinoma is 
transurethral resection possibly followed by chemotherapy or intravesical 
immunotherapy treatment. However, the high rate of recurrence and the potential 
to the progress as muscle-invasive raise much concern for the follow-up patients. 
There is a need to evaluate novel treatment strategies that can improve the 
efficacy of the current treatment. Testing of new therapeutic agents or drug 
regimens cannot be done initially in the clinics unless preclinical trials provide a 
rationale to change the current treatment modalities. As of today, there are two 
preclinical murine bladder cancer models: 1) the chemically induced bladder 
cancer model and 2) the xenograft model which involves the transplantation of 
human transitional carcinoma or carcinoma cells into immunodeficient or 
immunocompetent mice. Transitional carcinoma cells can be implanted to form 
heterotopic tumour (subcuetaneous injection) or orthotopic tumour (intravesical 
instillation). The xenograft model is preferred as it permits the labeling of 
carcinoma cells before implantation to allow the real-time tracking of carcinoma 
cells in the animal.  The subcutaneous model is useful in the investigation of 
tumourigenicity while the orthotopic model is useful in the study of tumour 
progression as carcinoma cells form tumours that reside in the organ of origin, 
providing a favourable model for evaluation of new treatment modalities. Part 2 
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of this chapter describes the optimization of a murine orthotopic bladder cancer 
model that is used to evaluate the effectiveness of the shortlisted TGFβRI 
















Choosing the appropriate cell line for the establishment of an orthotopic 
bladder cancer model relevant to our study 
To study the invasive behaviour of the carcinoma cells in vivo, we started with the 
selection of bladder cell line originating from high grade tumours with high 
invasive potential. Since the expression level of c-Met was found to correlate with 
tumour grade in human bladder cancer patients and poor prognosis was associated 
with high c-Met expression levels, it is preferable that the cell line chosen have a 
relatively high expression of c-Met with c-Met activity. Therefore, we assessed 
the level of c-Met expression across a panel of 4 commonly used human bladder 
carcinoma cell lines: HT1376, T24, J82 and UM-UC-3; and observed that UM-
UC-3 human bladder carcinoma cells expressed relatively higher levels of c-MET 
compared to the other human bladder carcinoma cell lines (Figure 28A). 
Furthermore, c-Met is constitutively active in UM-UC-3 (Figure 28B). 
 To investigate if c-Met expression of the bladder carcinoma cells correlates with 
their invasive behaviour, a matrigel-coated boyden chamber was used to compare 
the invasiveness of a low c-Met expressing human bladder carcinoma cell line 
HT1376 with a high c-Met expressing human bladder carcinoma cell line UM-
UC-3. 2.3 folds more UM-UC-3 carcinoma cells invaded the matrigel layer 
compared to HT1376 carcinoma cells (Figure 28C). This data demonstrated that 
higher levels of c-Met expression correlates with increased invasive behaviour of 
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bladder carcinoma cells; and the levels of c-Met expression can be a measure of 




Figure 28: c-MET expression level correlates with invasiveness in bladder 
carcinoma cell lines.  
(A) Left panel: Semi-quantitative RT-PCR was used to amplify fragment (410bp) of c-
Met from mRNAs of 4 human transitional cell carcinoma cell lines (HT1376, T24, J82 
and UM-UC-3 (UMUC3)). The graph displays the relative fold change in c-Met 
expression of T24, J82 and UM-UC-3 compared to HT1376. Right panel: forward and 
reverse primer sequence for human c-Met and Gapdh. (B) Immunoblot for c-Met 
phosphorylation (pc-MET) shows that c-Met is constitutively phosphorylated in UM-
UC-3 under resting state. c-Met is not activated in T24 and J82 cell lines. α-Tubulin 
was used as a loading control. (C) Left panel: crystal violet staining of HT1376 and 
UM-UC-3 cells that invaded the matrigel in the boyden chamber. Right panel: 
Fluorescence quantification of Calcein AM stained HT1376 and UM-UC-3 cells that 
invaded the matrigel in the boyden chamber. Bars represent mean + SEM. *p<0.05, 









The tumorigenicity of HT1376, T24, J82 and UM-UC-3 carcinoma cell lines were 
observed using a subcutaneous model as tumours formed can be monitored and 
measured with a vernier caliper. Each carcinoma cell line was injected 
subcutaneously into the flank of 3 athymic mice and observed for tumour growth 
for 31 days.  Only the tumours that were derived from UM-UC-3 carcinoma cells 
continued to grow and increase in volume (Figure 29). The invasiveness and 
tumorigenicity of UM-UC-3 bladder carcinoma cell line makes it an attractive cell 
line for the establishment of the orthotopic mouse bladder cancer model.  
 
 
Figure 29:  UM-UC-3 is tumourigenic in vivo.  
4 human bladder cancer cell lines (HT1376, T24, J82 and UM-UC-3 (UMUC3)) were 
subcutaneously injected into the left and right flank of nude mice to form tumours, as 
described in materials and methods. The dimension of the tumours were measured 
twice a week using a digital vernier caliper; and the first measurement was taken a 
week after injection. HT1376 was not tumourigenic. Tumours formed by T24, J82 
carcinoma cell lines regressed after 13 days. Tumours formed by UM-UC-3 carcinoma 
cell line grew and reached more than 1000mm
3
 in less than 25 days. Tumour volume is 
calculated using the formula: (length x width
2 
)/2. Each point on the curve represents 
mean +SEM. N=6  
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UM-UC-3 carcinoma cells exhibit a spindle like morphology characteristic of 
mesenchymal cells. To determine the in vitro morphological changes of UM-UC-
3 in response to A83-01 (TGFβRI inhibitor), UM-UC-3 carcinoma cells were 
treated with A83-01 and observed under a phase contrast microscope. In the 
presence or absence of HGF, UM-UC-3 carcinoma cells were observed to cluster 
and initiate cell-cell contacts under A83-01 treatment (Figure 30). It is important 
to note that UM-UC-3 carcinoma cells treated with HGF did not elicit a more 
mesenchymal phenotype, attributed to an already fully activated c-Met.  
 
Figure 30: UM-UC-3 responds to A83-01 (TGFβRI inhibitor) and resumes cell-
cell contacts with inhibition of TGFβRI.   
Phase contrast images of UM-UC-3 cells treated with 10µM A83-01 in the presence 
and absence of 5ng/ml of HGF. Top Panel: UM-UC-3 carcinoma cells were incubated 
with DMSO (drug vehicle) or A83-01 (TGFβRI inhibitor) for 3 days and cell 
morphology was examined and photographed using a phase-contrast microscope. 
Bottom Panel: UM-UC-3 carcinoma cells were incubated with DMSO or A83-01 for 2 
days prior to HGF treatment for 24 hours. HGF exposure did not induce any phenotype 
change as HGF receptor (c-Met) was constitutively activated in UM-UC-3 carcinoma 
cells. UM-UC-3 carcinoma cells treated with A83-01 initiated cell-cell contacts which 
were not observed in DMSO treated cells.    
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Method of tumour detection  
Physical examination with bladder palpation and urine inspection are one of the 
methods to confirm tumour growth; however, when a tumour becomes palpable 
and haematuria is observed, it often represents a late stage of bladder cancer and 
efficacy of treatment might be compromised. In order to detect tumours and treat 
mice before clinical signs appear, non-invasive in vivo imaging 
(Bioluminescence, Fluorescence and MRI) is required. Bioluminescence is 
preferred as the image acquisition time is short and signal is strong. This 
technique involves a photo-imaging device that detects light signals that arise 
from the catalysis of the luciferin (substrate) by luciferase.  
In order to detect the establishment and growth of UM-UC-3 tumours in the 
mouse bladder, UM-UC-3 carcinoma cells were generated to stably express a 
mammalian codon-optimized firefly luciferase2 that would react with its substrate 
(luciferin) for bioluminescence detection. When luciferin is intraperitoneally 
injected into the mice harbouring UM-UC-3-luc2 carcinoma cells in the bladder, 
luciferase of the UM-UC-3-luc2 carcinoma cells catalyse the oxidation of 





green light that shifts to red light in vivo at 37
o
C. The red light is detected by the 




Implantation technique       
The stable cell line, UM-UC-3-luc2, was inoculated into the bladders of 6-8 week 
old-mice through an angiocatheter; and retained in the bladder lumen of mice for 
3 hours (Figure 31). The lumen of the mouse bladder is lined with a film of mucin 
that consists largely of substances known as glycosaminoglycan (GAG). This 
GAG layer is thought to be the first line of defense of the urinary bladder against 
penetration into the bladder wall by bacteria and potentially harmful substances in 
the urine (www.ic-network.com/handbook.bladwall.html). Therefore, it is 
imperative that this GAG layer is disrupted or removed for UM-UC-3-luc2 cells 
to attach to the bladder wall. The bladder lumen of mice was pre-treated with 
0.2% trypsin for 30 min to elute the intercalated proteoglycans from the luminal 
surface, thus increasing the tumour take rate of 0-10% to 40-60%.  
The presence of tumours was confirmed using the bioluminescence in vivo 
imaging system a week after the implantation procedure (Figure 31).The major 
shortcoming of this procedure was the minimum incubation period of 3 hours that 
allowed UM-UC-3-luc2 cells to adhere to the bladder wall. During this incubation 
period, the mice were continuously under the influence of isoflurane induced 
anaesthesia.  This prolonged anaesthesia inevitably resulted in an increased 




Figure 31: Orthotopic implantation and in vivo detection of bladder carcinoma. 
Left picture: UM-UC-3 carcinoma cells harbouring the luciferase construct were 
instilled into the trypsin pre-treated bladder lumen via a 24G angiocatheter. UM-UC-3 
carcinoma cells were incubated in the bladder lumen for 3 hours while mice were kept 
warm with a 37
o
C heat plate and subjected to 1.5% isoflurane anesthesia. White arrow 
shows the distended bladder during implantation. Right picture: Bioluminescent 
intensity (BLI) image of orthotopically inoculated UM-UC-3 cells in the bladder after 
one week of implantation. Luciferin was injected intraperitoneally into the mice to 
observe tumour take; luminescence would be detected from mice which had tumour 
established while no signal would be detected if UM-UC-3 carcinoma cells did not 





Drug administration is a significant component in testing new therapeutic 
regimens and requires careful planning in optimizing the delivery of compound to 
the experimental animals while minimizing the potential adverse side effects. The 
route for administration of compounds is optimized for issues pertaining to 
compound stability, metabolism and excretion of compounds and compound 
solubility (selection of vehicle or solvent for drug delivery). The dosing 
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methodology which includes factors like frequency of administration and duration 
of treatment is critical as compounds have to be administered repeatedly and must 
not cause toxicity to the experimental animals.  
Since TGFβRI inhibitor (A83-01) is highly insoluble in diluents like Carboxy 
methyl cellulose, 0.5% Tween 80 and Saline which were commonly used for drug 
administration, its dissolution was much improved using DMSO. The intravenous 
route requires the compound to be readily soluble in a vehicle that does not cause 
osmotic shock or toxicity to the animal. Intravenous injection of high percentage 
of DMSO is toxic to the animal and thus could not be used. The compound was 
thus administered intraperitoneally (150µg/200µl/body; DMSO: Saline (3:2, v/v)) 
or orally (800µg/200µl/body; DMSO: Saline (1:4, v/v)) to animals.  The 
compound entered the bloodstream within half an hour after administration for 
both routes. To determine the final concentration of A83-01 that reach the blood 
stream and the time the drug takes to clear from the blood stream, blood samples 
were collected for analysis after 30 minutes, 2 hours and 4 hours after 
administration. . Drug concentration detected from the blood plasma was 1.2µM 
for oral administration at 30 minutes post administration and decreased to 0.3µM 
after 2 hours followed by 0.03µM after 4 hours; 4.25µM of A83-01 was detected 
in the plasma of mice 30 minutes after intraperitoneal injection and the plasma 
was cleared of the compound after 2 hours from the initial injection (Figure 32). 
The oral route was less efficient but the pharmacokinetics was more favourable 
over a longer period of time than intraperitoneal administration. However, when 
the compound present in the plasma was analysed using the HPLC technique, 
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double peaks were observed for the oral administration which suggested the 
possibility of a conjugated metabolite that might interfere with the outcome of the 
experiment. 
 
 Figure 32: Comparison of A83-01 
concentration in plasma of mice 
between oral and intraperitoneal 
administration. 
The graph shows the concentration 
of A83-01 detected in the plasma of 
mice at 30 minutes, 2 hours and 4 
hours after oral (grey bar) and IP 
(intraperitoneal) (black bar) 
administration.  Mice were gavaged 
with 800ug/200ul/body (equivalent 
to 9.4mM) of A83-01 and the drug 
concentration detected in plasma 
was 1.2uM at 30 minutes; 0.3uM at 
2 hours and 0.03uM at 4 hours after 
administration. For intraperitoneal 
administration, mice were injected 
with 150ug/200ul/body (equivalent 
to 1.7mM) of A83-01 and the drug 
concentration detected in the plasma 
was 4.2uM at 30 minutes.   
 
The intraperitoneal route of administration is preferred as this method produced 
the highest bioavailability and circumvented the problem with enteral absorptive 
issues. The vehicle for A83-01 was referenced against a published study in which 
A83-01 was diluted in DMSO: Saline (3:2, v/v) (Minowa, Kawano et al. 2009). 
Since the pharmacokinetic data showed that A83-01 administered through 
intraperitoneal injection was cleared from the blood stream within 2 hours, A83-
01 had to be administered with a daily dose of 150μg/body. 
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The efficacy of A83-01 in the treatment of the orthotopic bladder cancer model   
Tumour growth was monitored weekly by measuring the bioluminescence 
intensity of the tumour using the in vivo bioluminescent imaging system. BLI 
reading was high (~ 1e
9
 photons/sec) on the day of instillation (Day 0) as a high 
number of cells were retained in the bladder; the BLI reading dropped 
tremendously after a week (Day7) due to the inability of a large number of cells to 
adhere to the bladder wall and undergo apoptosis or removed during urination. 
The BLI reading entered the linear phase after Day14 and this signifies successful 
implantation and tumour growth (Figure 33).  
 
Figure 33: Monitoring in vivo 
tumour growth using 
bioluminescent imaging. 
Tumour was monitored weekly 
by peritoneally injecting mice 
with luciferin and imaged using 
bioluminescent imaging system. 
Top panel: BLI (bioluminescent 
intensity) image of mice from 
Day 0 to Day 35; Day 20 image 
represents the linear phase of the 
tumour growth (Day 14 to Day 
28). Bottom panel: Graph 
illustrates the trend of the 
weekly measured BLI reading. 
A drop in BLI reading was 
observed at Day 7 in which most 
of the cells that did not detach 
were removed through urination; 
cells which attached gave a BLI 
reading. Tumour reached the 
linear phase after Day 14 and 
grew exponentially and reached 
a plateau after Day 28.  
 
When tumours reach a bioluminescence intensity (BLI) of 5e
7
 photons/sec (~Day 
17 post instillation), mice were paired according to their bioluminescence 
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intensity; and for each pair, for 2 weeks, the control mouse was treated with drug 
vehicle (DMSO: Saline (3:2, v/v)) while experimental one was treated with A83-
01 diluted in DMSO: Saline (3:2, v/v).  
Bladder tumours usually shed cells into the urine and therefore, the urine of mice 
was collected a week after treatment to detect morphological changes in the 
bladder carcinoma cells due to A83-01. The urine was placed in cell culture 
medium and observed the following day. The cells from urine of tumour bearing 
mice treated with A83-01 clustered together, initiating cell-cell contacts while 
those from mice treated with vehicle (DMSO) conferred similar morphology to 
the UM-UC-3 cell line (Figure 34A). 
After 2 weeks of drug treatment, the tumors were fixed for 10 minutes by 
delivering 4% PFA via a catheter into the bladder before the bladder was 
surgically removed. The tumours were paraffin-embedded and the sections were 
Haematoxylin and Eosin stained and imaged. Carcinoma cells in mice treated 
with Vehicle were observed to invade through the bladder wall layers (Mucosa, 
Submucosa, Mucularis and Serosa) leaving behind pieces of untouched serosa 
(Figure 34B-C); while carcinoma cells of the A83-01 treated mice remained 
superficial (Figure 34D-G). Taken together, the data indicated that A83-01 
induced a change in cell morphology and altered the invasiveness of carcinoma 
cells. TGFβRI targeted therapy might help to prevent invasion into the bladder 
wall for patients with high grade T1 tumours and could also be applied to delay 






Figure 34: A83-01 affects the morphology of tumour-derived UM-UC-3 carcinoma 
cells and their ability to invade into the bladder wall. 
(A) Urine of mice collected a week after treatment with Vehicle (DMSO: Saline (3:2, 
v/v)) or A83-01 were cultured in the incubator with culture media without drug for 5 
days. Phase contrast images of cells that were shed into the urine of mice were taken 
and compared against the UM-UC-3 (UMUC3) carcinoma cell line. Cells from urine of 
tumour bearing mice treated with Vehicle were spindle-like, similar to the mesenchymal 
morphology of the parental UM-UC-3 carcinoma cell line; while those treated with 
A83-01 displayed different morphology which was observed to initiate cell-cell 
contacts.  (B-E) Haematoxylin and Eosin staining of orthotopically established UM-UC-
3 bladder tumours. (B) Mice treated with Vehicle displayed tumours with invasive 
phenotype in which UM-UC-3 carcinoma cells invaded the bladder wall. (C) Magnified 
insert of B showed that UM-UC-3 carcinoma cells invaded through the Mu (muscularis: 
muscle layer) and parts of the S (serosa); while (D) A83-01 treated UM-UC-3 
carcinoma cells did not invade through the bladder wall. (E) Magnified insert of D 
showed that A83-01 treatment affected the invasiveness of UMUC3 carcinoma cells as 
cells were retained within the M (mucosa) and did not invade through the SM 
(submucosa), muscularis and the serosa.  (F) Muscularis of bladders were 
histochemically labelled with anti-alpha smooth muscle actin (αSMA) and (G) the 
percentage of Muscularis invaded by UM-UC-3 was calculated using Image J analyses. 











The EMT inhibition assay was adapted for high throughput screening of targeted 
compounds and a robotic liquid handler was programmed to consistently deposit 
cells onto a spot to form a cell colony/well reproducibly in multi-well plates. To 
the best of our knowledge, this method of generating cell colonies via confined 
spotting technique has not been previously attempted. Furthermore, this method 
requires much shorter time as compared to the common alternative method which 
require at least 3 days for sparsely attached cells to grow and form cell colonies. 
Another key advantage of this EMT screen is taking the entire well instead of 
representative microscopic views for analysis which greatly decreases sampling 
biasness. The two parameters (Cell Count Ratio and Cell Dispersion Ratio) 
measured colony compactness in numbers and this increases the confidence in hit 
identification.    
Through the EMT drug screen, we discovered druggable targets TGFβRI, MEK, 
SRC and PI3K that might play significant role in EMT modulation and cancer 
progression. These four targets identified are crucial but does not represent all 
targets that are implicated in the EMT process. The library of compounds 
assembled for the screen comprised of a small subset of compounds that were 
developed by universities and the pharmaceutical industry and hence not a 
representative of all compounds identified to date. Efforts could be made to 
extend the EMT screen to include other diverse compound libraries for example 
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targeted compounds of metabolic diseases to allow the discovery of other potent 
EMT inhibitors.   
We have shown that compounds targeting TGFβRI, Mek, PI3K and Src are 
inhibitory to EMT-inducing growth factors: EGF, HGF and IGF-1 in cell 
dispersion, cell migration and modulating EMT markers. However, the efficacy of 
these targeted compounds in inhibiting other EMT-inducing growth factors like 
PDGF and VEGF was not determined. These targeted compounds were not 
screened against VEGF-A and VEGF-B which were reported to induce EMT in 
bladder cancer cells as NBT-II cells did not produce a significant cell dispersion 
response (Appendix 7). Moreover, the effect of PDGF and VEGF are more 
pronounced in vivo than in vitro models due to the presence of endothelial cells.  
We have identified the TGFβRI EMT signature in a c-Met driven system. This 
TGFβRI EMT signature comprise of genes that regulate focal adhesion and actin 
cytoskeleton reorganization. This signature provided evidence of the need for 
cooperation between TGF-β and HGF pathway in driving motility and invasion. 
The EMT signature identified here addressed the cell-substrate mechanism but 
lacked the cell-cell adhesion portion. It might be suggested that the cell-cell 
adhesion mechanism was impacted by the reorganization of actin cytoskeleton. 
Continuous effort has to be made to address this issue.   
We have successfully used the orthotopic bladder cancer model to validate the 
efficacy of the TGFβRI inhibitor in limiting bladder wall invasion. This model 
provides a good model to study the first steps of bladder wall invasion as cells are 
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implanted superficially onto the wall lining. To the best of our knowledge, we 
showed it for the first time in bladder cancer that a receptor kinase inhibitor was 
able to delay the invasion of bladder carcinoma cells into the bladder wall. This 
observation further affirms the results from the screen and bridges the gap 
between in vitro cell-based experiments and preclinical models. The studies pave 


















Epithelia neoplasia is initiated by genetic alterations leading to the inactivation of 
tumour suppressor genes and activating mutations of proto-oncogenes. Epigenetic 
changes are also critical in the transformation process by altering the expression 
level of key regulatory proteins including tumour suppressors. The transformed 
epithelial cells undergo considerable morphological changes, including partial 
loss of apico-basal polarity, actin microfilament and microtubule organization and 
exhibit uncontrolled proliferation leading first to a benign tumour mass before 
engaging into a malignant state. Angiogenesis is then initiated to support the 
metabolic needs of a malignant tumour mass once exceeding a few mm3. 
Subsequently, carcinoma cells still surrounded by a basement membrane 
designated as carcinoma in situ acquire additional genetic alterations and 
epigenetic modifications which can promote fragmentation and dissolution of the 
basement membrane allowing some carcinoma cells to invade into the 
surrounding stroma and intravasate into the blood or lymphatic vessels. Distant 
dissemination of carcinoma cells is an early event in tumour progression contrary 
to the accepted dogma that metastasis occur at a late stage of the disease. 
Circulating carcinoma cells that are able to escape cell death in the blood/lymph 
stream can potentially lodge in the parenchyma of distant organ to form micro 
metastases. Micrometastases are undetectable even using the most advanced 
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imaging techniques such as Magnetic resonance imaging (MRI) and Positron 
Emission Tomography (PET) scan.  The disseminated carcinoma cells remain in a 
dormancy-like state due to a balanced rate of proliferation and apoptosis or 
acquire a senescent status. Carcinoma cells eventually can resume growth by 
unknown mechanisms thus generating clinically detectable macrometastases. The 
dissemination of carcinoma cells originating from the primary tumour to other 
parts of the body is life-threatening since most therapeutics regimens fail to 
prevent this process. The very low proliferative carcinoma cells in micro 
metastases are likely to be insensitive to chemo and targeted therapeutic agents 
and escape immune surveillance. 
Metastasis was hypothesized to occur through the “seed and soil” theory 
introduced by Stephen Paget in 1889; in which the “seed” refers to the malignant 
cells that escape the primary tumour site  and the “soil” refers to the 
microenvironment in which the carcinoma reside in the distant organs.   
Carcinoma cells in metastases differ from those in the primary tumour in their 
transcriptomic and genetic alteration profiles and this may be accounted by the 
possibility that metastatic carcinoma originate from carcinoma cells in the 
primary tumour at different times during tumour expansion and progress 
independently from those in the primary tumour. This genetic divergence is 
further accentuated by strong evidence for clonal heterogeneity in the primary 
tumours. These recent findings are in agreement with the original hypothesis 
formulated by Nowell for clonal selection during progression (Nowell 1976).  
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Metastasis process is not governed solely by genetic alterations; recent data have 
suggested additional layers of epigenetic control over cells that metastasize 
(Augoff, McCue et al. 2012); (Baylin and Ohm 2006). Epigenetic reprogramming 
is dynamic and reversible; mostly the abrogation expression of tumour 
suppressors. These epigenetic programs include the methylation of cytosines in 
CpG islands that can affect directly gene transcription; or in cooperation with 
histone posttranslational modifications can either activate or repress gene 
expression by modifying locally chromatin structure. In addition, more than 1500 
micro RNA are critically involved in regulating levels of transcripts and proteins. 
Other non-coding RNAs are also recognized to modify the transcriptome.   
Grading of carcinoma is established according to their proliferative rate, extent of 
anisokaryosis and to the degree of dedifferentiation. Grading is still mandatory 
today and the best indicator of prognosis with staging. Carcinomas that cannot 
form glandular-like structure but rather acquire a fibroblastic-like morphology are 
always of worse prognosis. This observation in addition to the fact that the 
initiation of cell migration is very often associated with an epithelial 
mesenchymal transition (EMT) during embryogenesis, has led to the hypothesis 
that carcinoma cells in the primary tumour may have co-opted such a mechanism 
to disseminate.  
Carcinoma cells potentially can switch their phenotype from epithelial to 
mesenchymal or at least acquire an intermediate possibly metastable epithelial 
mesenchymal status before engaging into metastasis. The disseminated carcinoma 
cells can re-epithelialize in the distant sites or maintain a meta-stable state in 
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small metastases allowing carcinoma to disseminate from these secondary sites. 
EMT is a transient phenomenon and has been difficult until recently to capture in 
tumour biopsies. Such cells have now been documented in a large number of 
carcinoma of different origins. Among other evidence solitary colon carcinoma 
cells expressing nuclear β-catenin were identified at the invasive front within the 
stroma (Brabletz, Jung et al. 2001). The distribution of a large set of epithelial and 
mesenchymal markers has been established in more than 600 breast carcinoma 
samples revealing the presence of a significant number of carcinoma cells 
expressing mesenchymal markers.  Circulating tumour cells in breast carcinoma 
patients were found to express a spectrum of EMT phenotypes (Powell, Talasaz et 
al. 2012). In the present study, EMT was found to have a role in the deregulated 
activation of invasive growth and metastasis of bladder carcinoma model cell 
lines.   
Epigenetic reprogramming contributing to invasive growth is dependent on the 
environmental cues such as growth factors, oxygen content, nutrient availability 
and microenvironment composition. Although several cytokines and growth 
factors can promote cell proliferation, migration and protection from apoptosis, 
HGF optimally orchestrates the spatial and chronological events in this process. 
Moreover, HGF/c-Met signalling plays crucial roles in cancer progression, 
particularly in influencing tumour invasiveness and metastatic potential and 
down-regulation of c-Met decreased the tumourigenicity of cancer cells. It is 
challenging to pinpoint the period at which epigenetic reprogramming takes place 
in vivo, hence we attempted to uncover this process using an in vitro model of 
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EMT induced by HGF to analyse the transcriptome of cells undergoing phenotype 
switch. We identified a number of genes and pathways that are altered in the early 
steps (2 hour post-HGF treatment) in the EMT process. This early neoplastic 
process was observed with changes in expression of genes related to functional 
classes, such as interactors (Actg1, PVRL4, TGFβR2)  of adherens junction 
proteins and interactors (MAGI3, Cldn4, Actn1, Tjp2) of tight junction proteins. 
ErbB, MAPK and TGFβ pathways identified here are often dysregulated in 
cancers. Similar to other reports, c-Met signalling activates ErbB signalling and 
also downstream MAPK signalling. However, it is intriguing to find that TGF-β 
signalling is activated at an early stage of the process. Although TGF-β is a potent 
inhibitor of cell proliferation, it is believed that in tumour cells, TGF-β pathway 
loses its anti-proliferative response and acquires a pro-oncogenic role. In this 
analysis, in the presence of HGF, TGF-β pathway assumes an oncogenic role as 
inhibition with TGFβR inhibitor abrogated cell dissociation.  This finding 
correlates with other reports which show that TGFβ family ligands correlate with 
more aggressive phenotype of bladder cancer cell lines and deregulated TGFβ 
signalling led to enhanced migration and invasiveness of bladder cancer cells 
(Hung, Wang et al. 2008).  
The metastable state was represented by pathways important for tumour 
sustenance and invasiveness. Alteration of p53 pathway and Phosphatidylinositol 
4,5-biphosphate (PIP) pathway directly affects p53 and phosphatase and tensin 
homolog (PTEN) expression and stability. Mutation or alteration of p53 and 
PTEN expression were often found in tumours of advanced bladder cancer stages. 
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Mutations in p53 gene are associated with invasive phenotype and bad prognosis 
in bladder cancer. Genes that regulate focal adhesions Laminin, alpha 3 (Lama3), 
Lamc2, guanine nucleotide exchange factor Vav1 and Vav2 were deregulated. 
Lamc2 is highly expressed in advanced stages of bladder cancer. Although Vav1 
and Vav2 proteins were not reported in TCC tumours, Vav1 was reported to be 
ectopically expressed in pancreatic adenocarcinomas, neuroblastoma and 
melanoma while Vav2 was observed to be a critical regulator of growth-factor 
stimulated motility in human cancers. The Jak-Stat pathway was also detected in 
this study and this pathway is linked to acute inflammation. The connection of 
inflammation to cancer progression and invasiveness is well established. VEGF 
pathway was up-regulated in this study and the VEGF pathway is highly 
responsible for angiogenesis in cancer, an important process in bladder cancer 
progression. Patients with T2/3 stages of bladder cancer usually have angiogenic 
tumours displaying blood lakes in tumours and blood in urine (Elfiky and 
Rosenberg 2009); (Shariat, Youssef et al. 2010).  
TGF-β signalling is one of the modules which was then explored using 
phosproteomic analysis.  A transient activation of TGF-β signalling via 
phosphorylation of Smad2 C-terminus serine residues was found to occur at an 
early stage following c-Met activation. The inhibition of this phosphorylation 
attenuated the migration and invasive potential of carcinoma cells. This is also 
seen in breast cancer cells in which a transient activation of TGF-β signalling is 
required to switch to an invasive phenotype. The activation of TGF-β signalling in 
this HGF-induced system is not clearly understood. The central dogma suggests 
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that TGF-β but not HGF induce the phosphorylation of Smad2 C-terminus while 
some reports showed C-terminal phosphorylation of Smad2 in response to HGF in 
a TGFβ-independent fashion. We have shown that the HGF-induced 
phosphorylation of Smad2 C-terminus is TGFβRI-dependent since TGFβRI 
inhibition leads to a decrease in Smad2 C-terminus phosphorylation. We have 
also demonstrated that activation of TGF-β signalling is mandatory for cells to 
disperse and migrate under the influence of two other growth factors EGF and 
IGF-I. Under the influence of these growth factors, TGF-β signalling promotes 
aggressiveness of carcinoma contrary to its suppressive role in normal cells. TGF-
β signalling acts as a converging point for the three growth factors tested and 
should be taken into consideration when treating cancers with over-expression or 
constitutively active RTK. 
In addition to Smad2 C-terminus phosphorylation, we have also investigated 
phosphorylation of the linker region and its impact on the phosphorylation of the 
C-terminus. ERK was found to phosphorylate Smad2 at the linker region in 
agreement with the observation with previous studies in which the linker region of 
Smad2 is phosphorylated at several serine/threonine residues through growth 
factor mediated MEK-ERK axis activation. Inhibition of MEK resulted in 
decreased cell migration, invasion and colony forming ability (Figure 34). The 
Smad2 linker region phosphorylated by ERK is suggested to be important for 
invasiveness as some reported the nuclear localization of Smad2 with 
phosphorylated linker regions in invasive late stage colorectal carcinoma 
(Matsuzaki, Kitano et al. 2009). However others have reported that 
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phosphorylation of Smad2 at both linker and C-terminus enhanced cell growth by 
up-regulation of c-Myc.  It is unclear whether Smad2 linker or C-terminus region 
is fully responsible for the progression of bladder carcinoma as inhibition of 
phosphorylation of either one region results in smaller tumour size. However, we 
do observe that carcinoma cells with non-phosphorylating Smad2 linker (Smad2 
dnL) were less tumorigenic compared to carcinoma cells with non-
phosphorylating Smad2 C-terminus (Smad2 dnC). Inhibition of both regions’ 
phosphorylations using a combination of compounds (A83-01 and PD0325901) 
greatly reduced the colony forming ability of carcinoma cells (Figure 34). In 
addition, inhibition of Smad2 linker phosphorylation led to an increase in Smad2 
C-terminus phosphorylation and inhibition of Smad2 C-terminus phosphorylation 
led to an increase in phosphorylation of ERK and Smad2 linker region. The 
phosphorylations of the two regions of Smad2 are cross-regulated; such type of 
regulation is required for the progression in regulating cell growth and 





Figure 35: PD0325901 reduces colony forming ability. 
Equal numbers of UM-UC-3 cells (5x10
4
) were seeded into 24-wells pasltic dishes and 
treated with or without A83-01 (TGFβRI inhibitor) or PD0325901 (MEK inhibitor) at 
the indicated concentrations over a period of 14 days. Colonies were visualized by 
crystal violet staining. Top graph: Quantification of colony numbers in A83-01 treated 
UM-UC-3 carcinoma cells. Middle graph: Quantification of colony numbers in 
PD0325901 treated UM-UC3 carcinoma cells. Bottom graph:  Quantification of colony 
numbers in A83-01 and PD0325901 treated UM-UC3 carcinoma cells. Quantification 
of colony number, representative of three independent experiments.  
 
Knowledge in invasive growth and tumour progression led to the development of 
new compounds for targeted therapeutics. Most of the compounds were initially 
identified and optimized using proliferation inhibition assays. The ten major 
hallmarks of cancer were reviewed recently and constitute a logical framework to 
target cancer progression (Hanahan and Weinberg 2011). The 10 hallmarks of 
cancer include sustaining proliferative signalling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, 
activating invasion and metastasis, genome instability and mutation, tumour 
promoting inflammation, avoiding immune destruction and deregulating cellular 
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energetics. Compounds that interfere with each of these hallmarks have been 
developed.  There are a number of approved drugs targeting the capability to 
sustain proliferative signals via inhibition of the family of EGF receptors such as 
gefitinib (Iressa) or erlotinib (Tarceva), two EGFR kinase inhibitors used to treat 
lung cancers with mutated EGFR; and trastuzumab (Herceptin), an antibody 
against ErbB2 gene used to treat breast cancers.  Some attempts have been made 
to target angiogenesis induction, mainly to destroy the vascularization in tumours. 
Several classes of angiogenic modulators such as anti-VEGF antibody (Avastin), 
a triple angiokinase inhibitor (BIBF-1120), MMP inhibitor (Neovastat), anti-
endothelium drugs (combretastatins) were tested in clinical trials. Multiple 
approaches have been attempted to interfere with invasion and metastasis by 
designing drugs that target the ATP pocket of c-Met and developing neutralizing 
anti-HGF antibodies. Small molecular weight compounds such as PF04217903 
and PF02341066 have reached phase1 clinical trial while JNJ38877605 reached 
phase2 clinical trial targeting advanced refractory tumours. Numerous clinical 
trials based on single tyrosine kinase inhibitors (TKI) have been conducted over 
the last decade demonstrating a significant albeit transient response to treatment. 
However, in the large majority of these patients resistance against the TKI therapy 
is eventually observed. This gain in resistance is partly due to the acquisition of 
novel mutations in the intended target or mutations in proteins downstream to the 
initial chosen target or activation of different pathways that empower carcinoma 
cells with the ability to survive. Lung carcinoma patients who initially responded 
to EGFR TKI treatment acquired resistance and cancer relapsed. Studies have 
133 
 
shown that the acquired resistance was a result of a secondary mutation in EGFR, 
T790M (Pao, Miller et al. 2005). In addition, attempts to investigate the cause of 
treatment failure revealed that the inhibition of any one of the receptors result in 
up-regulation of the other pathways. For example, EGFR TKI gefitinib resistant 
cells display IGF-1R hyper phosphorylation with constitutive association of 
(Insulin receptor substrate 1 (IRS-1) and PI3K that counteracts the ability of 
gefitinib in inhibiting cancerous cell growth (Guix, Faber et al. 2008). Baselga has 
also demonstrated that treatment with mammalian target of rapamycin (mTor) 
inhibitors result in up-regulation of IRS (O'Reilly, Rojo et al. 2006). Moreover, a 
given hallmark of cancer is governed by several partially redundant pathways, 
inhibition of one key element or pathway might not eliminate a hallmark 
capability completely. Selective co-targeting of multiple biochemical pathways or 
a common node might result in a more effective therapy.  
We extended the concept of cancer hallmarks by adding EMT to the circuitry. 
Biochemical pathways that govern each cancer hallmark converge at some point 
and are implicated in the EMT process. We screened small molecular weight 
compounds initially designed to interfere with proliferation in an attempt to 
identify those that can inhibit EMT. Our laboratory in collaboration with Jean 
Pierre Abastado has thus demonstrated that the EMT inhibitors identified by our 
laboratory not only inhibit growth factor induced migration but also interfere with 
the actions of tumour promoting polymorphonuclear myeloid-derived suppressor 
cells (PMN-MDSCs) (Toh, Wang et al. 2011).  Using this global approach, we 
target multiple hallmarks in parallel, combating proliferation, inflammation and 
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invasion and metastasis. With the right combination of drugs, new treatment 
modalities can be designed to target both the tumour and the microenvironment 




Much effort has been made in the past decade to target the proliferative capability 
of carcinoma cells but all the therapeutic tools to date have limited efficacy and 
some therapeutic regimens may trigger additional processes which select for more 
aggressive and therapy-resistant cells. These carcinoma cells adapt and reduce 
their dependence on a particular hallmark and heighten the activity of other 
hallmarks leading to invasiveness and metastasis. This invasive and metastatic 
behaviour can be explained by cells seeking less hostile and new niches to renew 
tumour growth and also gain access to nearby pre-existing tissue vasculature. 
Mechanisms that govern invasion and metastasis are utmost important in 
elucidating the mechanisms of cancer pathogenesis. Our laboratory analysed the 
transcriptome of HGF-induced cells over time and uncovered the sequence of 
gene/pathway activation and the cascade of signalling events downstream to 
HGF/c-Met signalling. This study focussed only on a subset of the signal 
transduction pathways from one activated receptor and hence more exhaustive 
studies using this approach should be carried out to unravel the mechanisms and 
identify the signalling node responsible for invasive growth and metastasis. These 
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studies should provide valuable indicators for the development of new targeted 
therapies.  
 
Inhibiting EMT: a strategy to target invasive growth and metastasis 
 
Can invasive growth and metastasis be targeted? A concept emerged based on 
research in invasive growth and metastasis over the past decade implicating EMT 
as a process by which transformed epithelial cells can acquire attributes for 
invasion and metastasis. EMT is a multifaceted program and many biochemical 
pathways that affect other cancer hallmarks participate in the EMT process. It is 
difficult, however not impossible, to identify targetable EMT drivers. Advancing 
towards personalized medicine, administration of drugs will depend on the profile 
of the patient and the biopsies in which different tumours will display distinct 
deregulated pathways and certain enhanced hallmarks. A single agent can no 
longer be effective in the treatment of cancer due to the mechanisms activated by 
the carcinoma cells to survive. Combinatorial drug therapy may be a better option 
to target two or more hallmarks especially when EMT inhibitors are used. The 
notion of screening existing or newly developed compounds for their EMT 
inhibiting effects will aid in the establishment of a set of EMT inhibitors that may 
prove useful in executing combinatorial drug therapy.      
Most logical targets for invasion and metastasis are c-Met and TGFβR, however 
not many advances have been made to target c-Met and TGFβR in the clinic. 
Strategies to inhibit TGF-β signalling include TGF-β antisense approaches that 
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showed reactivation of tumour-specific immune responses and patients become 
more susceptible to different therapeutic regimens (Iyer, Wang et al. 2005). 
TGFβ2 antisense oligonucleotide entered phase II/III trials to treat high grade 
gliomas and phaseI/II trials to treat pancreatic cancer. Monoclonal antibodies 
against TGFβ2 and TGFβ1 successfully completed phaseI/II trials. However, the 
success of targeting TGF-β signalling has been limited due to toxicity of drugs or 
to vast pleiotropic effects leading to physiological imbalances. The aim of the 
TGF-β targeted therapy must be directed against the double-edge sword of TGF-β 
to enable inhibition of the pro-oncogenic features and the proper restoration of 
anti-oncogeneic effects. Understanding the cross talk between TGF-β and RTK 
signalling is important for the development of proper anti-cancer concepts 
targeting TGF-β.  
Options to inhibit HGF/c-Met signalling are kinase inhibitors designed to block 
the ATP pockets of c-Met and neutralizing antibodies designed to block ligand-
mediated c-Met signalling. In some circumstances, c-Met can be activated in a 
ligand-independent manner and is required for tumour cell signalling and 
survival; and this was demonstrated by a report using RNA interference against c-
Met (Shinomiya, Gao et al. 2004). Two laboratories have shown promising data in 
which one of the laboratory engineered a soluble form of c-Met and inhibited 
ligand-independent activation of c-Met (Coxon, Rex et al. 2009) while the other 
laboratory induced shedding of c-Met via a monoclonal antibody (DN30) that 
target the extracellular portion of c-Met, creating a decoy c-Met to prevent c-Met 
activation (Pacchiana, Chiriaco et al. 2010). Decoy c-Met impaired tumour cell 
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expansion and angiogenesis, inhibiting tumour growth and metastasis in mice. 
However, the duration of the experiment was not extended to document tumour 
relapse. Moreover, inhibition of a single receptor might lead to the up-regulation 
of other pathways; and TGFβRI was shown by our laboratory to be a converging 
point of growth factor signalling, a combination of c-Met antibody and a TGFβRI 
inhibitor might work more effectively to prevent cancer spread or relapse.     
Another possible drug combination is MEK and TGFβR inhibitors. Cancers, 
especially bladder carcinoma, are found with frequent Ras mutations, rendering 
RTK inhibitors ineffective. A large body of literature suggests oncogenic RAS 
signalling plays an important role in switching TGF-β signalling from tumour 
suppressive to pro-oncogenic (Lehmann, Janda et al. 2000). Ras-MAPK 
signalling interferes with TGF-β signalling at the level of Smad2/3 activation and 
influences the composition of Smad-dependent transcription factor complexes, 
resulting in the transcription of a different set of genes. Ras and Smad-dependent 
transcription factors can also interact and cooperatively regulate transcription of 
target genes. Carcinoma cells in this case retain a functional TGF-β/Smad 
signalling; however the tumour suppressive functions were inhibited while 
malignancy increased. The mechanism of the synergy between oncogenic Ras and 
TGF-β signalling is just beginning to be resolved. In MDCK cells, Raf-mediated 
autocrine loop of TGF-β is required for the sustained activation of Raf-MAPK 
induced EMT and cell invasion. In human hepatocellular cells, hyper activation of 
MEK-ERK signalling inhibit the up-regulation of  the NADPH oxidase, NOX4, a 
protein essential for mitochondrial-dependent apoptosis, allowing cells to escape 
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from TGF-β induced apoptosis (Caja, Sancho et al. 2009). The cooperation of 
oncogenic Ras and TGF-β signalling induced the secretion of PDGF and up-
regulation of PDGF receptors upon EMT, activating PI3K and promoting β-
catenin accumulation in the nucleus (Fischer, Fuchs et al. 2007). In pancreatic 
adenocarcinoma, oncogenic K-Ras-ERK signalling promoted TGF-β induced 
transcriptional down-regulation of Phosphatase and tensin homolog (PTEN) 
which causes an increase in cell proliferation and tumour expansion in pancreatic 
cancer (Chow, Quach et al. 2007). Animal studies demonstrated that TGF-β 
induced EMT is not sufficient for the acquisition of invasive features and requires 
activated Ras (H-RASV12) to alter the TGF-β response and confers metastatic 
potential (Zavadil 2009). Moreover, our data shows that inhibition of MEK results 
in K-Ras positive tumour shrinkage and tumour profile shows an increase in 
Smad2 C-terminus phosphorylation, potentially up-regulating the canonical TGF-
β /Smad core signalling. However, our in vitro data shows that the effect of MEK 
inhibitors are compensated in the presence of growth factors, hence targeting 
MEK itself is not an effective option as the effect of the drug will be compensated 
by the growth factors present in the serum of cancer patients; and result in an 
inevitable relapse. Co-targeting of MEK and TGFβRI disrupts the oncogenic Ras-





Chemotherapeutics and EMT inhibition 
 
Chemotherapy has been reported to induce EMT by several mechanisms in 
carcinoma cells. EMT has been recognized as a critical step in the process of 
metastasis leading to cancer spreading and treatment failure due to acquired 
resistance. Cisplatin-resistant human tongue carcinoma cell lines display 
mesenchymal features with enhanced invasiveness and motility attributed by 
down-regulation of EMT gene repressor miRNAs miR-200b and miR-15b. 
Ectopic expression of miR-200b and miR-15b with miRNA mimics effectively 
reversed the phenotype of EMT (Sun, Yao et al. 2012). Cisplatin-resistant ovarian 
carcinoma cells were found to overexpress EMT-related transcription factors, 
Snail 1, Snail 2, Zeb2 and Twist2, and reduction in expression of Snail 1 and 
Snail 2 resensitized the cells to cisplatin (Haslehurst, Koti et al. 2012). 
Chemotherapeutic drug, oxaliplatin, induced EMT through Fas signalling, 
resulting in a decrease in epithelial markers and an increase in mesenchymal 
markers accompanied by an increase in motility (Zheng, Cai et al. 2013). 
Chemotherapeutic agents such as cyclophosphamide and epirubicin in 
combination with 5-fluorouracil used for breast cancer treatment induced EMT by 
activating EGFR through elevated expression of amphiregulin, thereby inducing 
expression of Twist 1 and activation of NF-kB (Li, Chen et al. 2011).  
In bladder cancer, coupling chemotherapeutics with EMT inhibition and anti-
angiogenesis therapy might be a plausible solution. Muscle invasive bladder 
cancers are characterized by haematuria and the presence of blood lakes within 
the tumours, treatment regimens that interfere with angiogenesis should be 
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considered a feasible therapeutic strategy. Sequential treatment of mesenchymal 
human bladder carcinoma cells with vandetanib targeting VEGFR and EGFR 
displayed improved cisplatin sensitivity (Li, Yang et al. 2010). BIBF-1120, a 
triple angiokinase inhibitor, has been shown to inhibit tumour growth in lung and 
pancreatic preclinical models (Kutluk Cenik, Ostapoff et al. 2013). Post BIBF-
1120 treatment of tumour tissues showed increased active caspase 3 with 
improved sensitivity to chemotherapy.  However, it should be noted that tumour 
progression is dynamic and carcinoma cells have a tendency to reduce 
dependency for a certain hallmark and gain others; hence patients undergoing 
treatment have to be monitored closely to detect any switch in events to enable the 



























In this study, we utilised an in vitro HGF-induced EMT in a bladder carcinoma 
model cell line to delineate the signalling pathways that drive invasiveness. 
Through a small molecular weight compound screen, we identified inhibitors of 
EGF, HGF and IGF-1-induced EMT. Using an orthotopic bladder cancer model, 
we showed that A83-01 (a TGFβRI inhibitor identified through the screen) 
delayed the invasion of human bladder carcinoma cells (UM-UC-3) into the 
bladder wall. Our gene expression profiling showed that HGF/c-Met signalling 
triggered other signalling pathways for EMT and tumour progression. HGF/c-Met 
signalling activates the MEK/ERK axis which in turn phosphorylates the Smad2 
linker region, thereby regulating the expression of Snail1 and Zeb1. HGF/c-Met 
signalling results in the activation of TGFβRI (by an unknown mechanism) which 
in turn phosphorylates the Smad2 C-terminus region, thereby regulating the 
expression of Twist. In addition, we have shown that phosphorylated Smad2 
linker region is important for tumorigenicity while phosphorylated Smad2 C-





Figure 36: A proposed model for HGF/c-Met induced EMT and tumour 
progression. 
Compounds targeting PI3K, Src, MEK and TGFβRI were identified in the small 
molecular weight screen. These compounds inhibited HGF-induced up-regulation of 
MMP13 and down-regulation of E-cadherin. HGF/c-Met signalling activates the 
MEK/ERK axis resulting in the phosphorylation of Smad2 linker region, thereby 
regulating the expression of Snai1 and Zeb1. HGF/c-Met signalling also activates the 
TGFβRI/Smad2 axis, resulting in the phosphorylation of the Smad2 C-terminus region, 
thereby regulating the expression of Twist. HGF/c-Met/MEK/ERK/Smad2 linker 
region axis might play a role in tumorigenicity; TGFβRI/Smad2 C-terminus axis might 
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Genes that are differentially expressed in both EGF and HGF treatment. 
Upregulated by both EGF and HGF Down-regulated by EGF and HGF 
Dusp7 Glb1l2 Narf Ripk3 Zfp36l1 Psme2 Krt16 
Efhd1 Glipr2 Ncdn Rnd1 Zfp36 Ptges Krt1-5 
Tspan5 Gnb4 Nek6 Rock2 Xdh Ptplb Krt13 
Tspan2 Gnl2 Ngf Rrp8 Wnt6 Ptprf Add3 
Efhd2 Gpr126 Niacr1 Rrp1b Wfdc15a Pvrl1 Aes 
Egr1 Gprc5a Nid67 Rras2 Sh3yl1 Pafah2 Afap1l2 
Ttc9 Gpsm1 Nol8 Sema3c Ucp2 Pcmtd2 Klhl24 
Ttc39b Hbegf Nrp2 Scmh1 Tspan8 Pdcd4 Krt1 
Ubash3b Hk2 Nrg1 Runx1 Tspan1 Ocln Klf13 
Ehbp1l1 Hlx Nppb Sertad2 Serpinb8 P2rx4 Agrn 
Ttll4 Hmga1 Nup153 Serpine1 Trim29 Nupr1 Klf3 
Vegfa Hpse Nuak2 Sfrs2ip Tob1 Nudt1 Aim1 
Ehd3 Hs3st1 Orc1l Sestd1 Tnks1bp1 Nt5dc2 Aldh3a1 
Elf4 Htra1 Odc1 Sgms2 Sepp1 Nrep Aldh6a1 
Vcl Iffo2 Obfc2a Abcb1b Tmem9 Npepo Alkbh7 
Elk3 Ing5 P2ry2 Abcb1a Selenbp1 Nqo1 Ka11 
Usp31 Inpp4b PVR Smap2 Scrn1 Notch1 Arid5b 
Eml4 Itga2 Pak1ip1 Abl2 Scp2 Nme7 Atf5 
Usp24 Itga3 Pard6b Slc25a30 Rxra Nme3 Kb15 
Emp3 Kank1 Papd5 Abhd2 Tecr Nisch Kbtbd4 
Enc1 Kcnn4 Pctk2 Abhd10 Tgfbi Nfix Bad 
Enpp1 Kif13a Pdpn Abcg1 Rpain Ndufa2 Jund 
Epha2 Klf6 Pelp1 Smc4 Tle3 Nap1l2 Jup 
Ercc1 Klk10 Pex11g Acap1 Tmco6 Ncor2 Barx2 
Ereg Lama3 Phlda1 Actn1 Spon2 Mylip Bbs9 
Ets1 Lamb1 Phtf2 Adam8 Robld3 Mt1a Bcam 
Etv4 Lamb3 Pik3cb Snx18 Sqle Msln Bcl11b 
Errfi1 Lamc2 Pik3cd Snf1lk2 Rhbdl3 Mpzl2 Id4 
Exo1 Lass6 Pim3 Afap1 Srebf2 Moxd1 Igfbp5 
Ugcg Ldlr Pitpnc1 Adfp Rhbdl2 Mospd3 Hoxd10 
Uck2 Lpcat1 Pip4k2a Adamts6 Rexo2 Mmp15 Bhlhe40 
Extl3 Lrp8 Plk2 Aen Syde2 Mif4gd Dsp 
F3 Lrrfip1 Plaur Smtn Renbp Mid1 Cdh13 
Fads3 Lsm11 Plscr1 St3gal4 Tacstd2 Mgst3 Cdkn1c 
Fam129b Macf1 Plk3 Srgap2 Tcfap2a Mgst1 Grhl3 
Fam132b Magi3 Plscr2 Akr1b10 Tctex1d2 Metrn Epcam 
Zyx Mboat1 Pmepa1 Akr1b7 Rcan1 Mettl7a Fgfr3 
B 
 
Zfp36l2 Mesdc1 Ppp1r12a Src Rapgefl1 Mgmt Fzd1 
Far1 Mfap3l Polr1b Spry2 Ranbp3l Mal2 Gata3 
Fat1 Mlf1ip Prkca Akr1b8 Rab3d Map3k9   
Fez2 Mllt4 Procr Alkbh Rab38 Mblac2   
Fhdc1 Mmd Prr5 Sox9 Rab25 Mcee   
Fhl2 Mmp10 Prrg4 Soat1 RT1-DMb Lztfl1   
Zeb1 Mprip Prss22 Ankrd50 RT1-DMa Ly6d   
Fhl3 Mmp3 Ptgs2 Stard13 Pde7a Lynx1   
Fignl1 Mmp13 Pthlh Tgfa Pdgfa Lphn1   
Whsc1 Mthfd1l Ptk2b Thbs2 Pecr Lss   
Flrt2 Mtap Ptpn12 Areg Phyh Lass3   
Flrt3 Msn Ptpre Cav1 Pias3 Lamb2   
Flt1 Mtr Ptprm Cd44 Pir Lad1   
Fnbp1l Mtmr10 Ptprz1 Ccnd1 Plb1 Lage3   
Fosl1 Mthfd2l Rasa1 Tpr Pld3 Lama5   
Vof16 Mybbp1a Rapgef2 Cxcl1 Pnrc1 Krt4   
Fst Myc Rai14 Dusp6 Pof1b Krt75   
Fv1 Mybl1 Rbms1   Prkag2 Krt17   
Fxyd5 Myo1b Rasa3   Prkcdbp Krt19   
Gch1 Myof Rhpn2   Prtfdc1 Krt2   





Genes that are differentially expressed in at least 3 time-points (326 genes 
including 54 probes). 
10701865 10700910 Cpeb2 Fras1 LOC690830 Pgap1 Slc14a1 
10705411 10700989 Cpne5 Fxyd5 Lama3 Phf17 Slc20a1 
10707620 10701309 Cspg4 Gba2 Lamc2 Phlda1 Slc24a6 
10721700 10701605 Csrnp1 Gdnf Lgr4 Pik3ip1 Slc2a5 
10737460 10940508 Cxcl1 Gjb2 Lif Pitpnc1 Slc30a7 
10748440 10940546 Cxcl10 Gjb4 Limk2 Plau Slc44a2 
10758724 Abcg1 Cyp3a9 Glrx1 Lmo1 Plaur Smad7 
10787805 Adam8 Cyp4f39 Gne Lpar5 Plk1 Smox 
10791650 Afap1l2 Cyth1 Gprc5a Lrrc57 Plk3 Snf1lk2 
10793607 Agpat9 Dck Gpsm1 MGC105649 Plscr1 Sprr1al 
10794544 Aim1 Dctd Gpsm2 Mast4 Ppard Spry2 
10799084 Aloxe3 Ddit4 Hbegf Mbp Ppfibp2 Srxn1 
10805088 Amac1 Depdc1 Hic1 Megf9 Pragmin St3gal1 
10805597 Ankrd50 Dhcr7 Hlx Mid1 Prl8a7 St3gal6 
10817100 Areg Dhrs9 Hmmr Mir483 Procr St5 
10817102 Arl5b Dlgap5 Hmox1 Mllt3 Prrg4 Stam 
10817105 Arsj Dnajb4 Hpcal1 Mmd Ptgs2 Stk40 
10817111 Aspm Dsg3 Hpse Mmp13 Pthlh Syde2 
10817119 Atg9b Dtl Hr Mmp15 Ptpre Synm 
10821105 Atmin Dtx4 Id1 Mmp3 Ptprm Synpo 
10824719 Atp13a4 Dusp1 Idh1 Mocos Ptrh1 Tgfa 
10824726 Atxn1 Dusp10 Ier2 Mxd1 Pxn Tgfb1 
10839872 Auts2l Dusp5 Igsf9b Mxi1 RGD1305254 Tgfbi 
10853391 Axin2 Dusp6 Il1a Myl9 RGD1306556 Tgfbr3 
10856998 B3gnt2 Ednra Il1rn Ndc80 RGD1311307 Tgm1 
10873027 Barx2 Egr1 Il24 Nedd9 RGD1563437 Timp1 
10874858 Bbs7 Ehd3 Irs1 Ngf RGD1564081 Tlcd1 
10881468 Bnip3l Emp3 Itpkc Niacr1 RGD1564984 Tm4sf1 
10884158 Brca2 Enc1 Junb Nid2 Rab38 Tmc7 
10885613 Capn8 Enpp1 Kcnn3 Nid67 Rap2b Tmem79 
10890904 Casc5 Eppk1 Kctd11 Notch1 Rasa1 Tnfrsf26 
10891594 Casp7 Ercc1 Kif20a Nppb Rasl11b Trib1 
10897037 Ccdc80 Ereg Kif23 Nrep Rhbdl3 Trim59 
10901713 Ccnb1 Ern1 Kif2c Nrg1 Ripk4 Trim62 
10902762 Ccnb2 Errfi1 Klf6 Oaf Rnf145 Trpv3 
10908670 Ccng2 Extl2 Klk6 Obfc2a Runx1 Tspan5 
10908914 Ccrn4l Fam107b Krt15 Odc1 Selm Ttc9 
10920626 Cd34 Fam110c LOC100125365 P2ry1 Sema4b Txnrd1 
10922779 Cdkn1a Fam43a LOC100233213 P2ry2 Sema7a Ubash3b 
10924441 Celsr2 Fat2 LOC100363984 PVR Serpine1 Uck2 
10930342 Cenpf Fermt1 LOC100365935 Pard6b Sertad1 Vof16 
10933769 Cep57 Fgfr3 LOC290508 Pawr Sertad4 Wdr19 
10722718 Cited2 Fkbp6 LOC305806 Pcdh1 Setd7 Wnt4 
10741865 Ckap2 Flt1 LOC363060 Pcyox1l Sgms2 Xkr6 
10817117 Cnot6l Fn1 LOC679752 Pdgfc Sgol2 Zswim4 
10821067 Cnst Fosl1 LOC683522 Pdpn Sh2d5  































































































HGF - A83-01 intersection group (280 genes) 
10703888 Actn1 Dusp6 Gprc5a Mmp15 Pmepa1 Sema3c 
10705411 Adamts6 Ech1 Gstt2 Mmp3 Pnrc1 Serpine1 
10707620 Aen Efhd2 Gstt3 Mpzl2 Ppp1r12a Sertad2 
10710087 Akr1b10 Egr1 Hbegf Mt1a Prkcdbp Sestd1 
10758724 Akr1b7 Ehbp1l1 Hbp1 Mtap Prr5 Sgms2 
10787958 Aldh3a1 Ehd3 Hk2 Mthfd1l Prrg4 Sh3yl1 
10801135 Ankrd50 Elf4 Hlx Mtmr10 Prss22 Slc1a5 
10815869 Areg Elk3 Hmga1 Mtr Ptges Slc20a1 
10817119 Arrb1 Emp3 Htra1 Mybl1 Ptgs2 Slc44a2 
10856998 Arsj Enc1 Id2 Myof Ptk2b Slc4a7 
10867832 Atf5 Epgn Idh1 Nek6 Ptpn12 Slc6a9 
10877684 Axl Epha2 Iffo2 Ngf Ptpre Slc7a6 
10884158 Baz1a Ephx1 Igfbp5 Niacr1 Ptprm Snf1lk2 
10885613 Bcar3 Ercc1 Inpp4b Nid67 Ptprz1 Snx18 
10889657 Bspry Ereg Itga2 Nme3 RGD1305347 Soat1 
10890904 Calml4 Errfi1 Itga3 Nppb RGD1310935 Spry2 
10908670 Camsap1l1 Ets1 Kcnn4 Nrep RGD1311307 St3gal4 
10912282 Capn8 Etv4 Kctd11 Nrg1 RGD1312026 Stxbp6 
10924084 Car12 Extl3 Klf6 Nuak2 RGD1560248 Tacstd2 
10930564 Car5b F3 Krt15 Nup153 RGD1561161 Tead1 
10930580 Casp3 Fads3 LOC100125362 Nupr1 RGD1561381 Tgfa 
10930598 Cd44 Fahd2a LOC305633 Obfc2a RGD1561394 Tgm1 
10930614 Cenpe Fam129b LOC686933 Odc1 RGD1563508 Thbs2 
10930618 Cenpf Far1 LOC688459 PVR RGD1565002 Tm4sf1 
10938288 Cflar Fat1 LOC689074 Pard6b RGD1565007 Tmem131 
10821067 Cpa6 Fez2 Lama3 Pctk2 RT1-DMb Tmem176a 
10845605 Cpeb2 Fhdc1 Lamb3 Pdcd4 Rab38 Tmem176b 
10901956 Csgalnact2 Fhl2 Lamc2 Pdpn Rai14 Tnfrsf26 
10700054 Cttnbp2nl Fhl3 Lass3 Pex11g Rapgef2 Tpr 
10940470 Cxcl1 Flrt2 Lrp8 Phlda1 Rasa1 Tsc22d2 
10940546 Cyp3a9 Flt1 Lyrm2 Pik3cb Rasa3 Tsku 
10940568 Cyr61 Fnbp1l Macf1 Pik3cd Rbms1 Tspan1 
10940593 Dapk2 Fosl1 Mblac2 Pim3 Rhbdl3 Tspan8 
10940627 Dbp Fst Mgmt Pir Rif1 Ttc39b 
10940628 Ddah2 Fut1 Mgst3 Pitpnc1 Rnd1 Ttll4 
10940647 Dhrs9 Gbas Mki67 Plaur Rras2 Vcl 
10940689 Dock5 Gdnf Mllt4 Plk2 Runx1 Vegfa 
Abcb1b Dock8 Glb1l2 Mmd Plk3 Scmh1 Vof16 
Abcg1 Dtx4 Glipr2 Mmp10 Plscr1 Scp2 Wnt6 
















NBT-II cells were treated with 100ng/ml of VEGF-A for 3 days and cell 
morphology was examined and photographed using a phase-contrast microscope. 


















(A) UM-UC-3 was exposed to 10µM A83-01 for 2 hours per day for one week and cell 
morphology was examined and photographed using a phase-contrast microscope. UM-
UC-3 carcinoma cells treated with A83-01 initiated cell-cell contacts and (B) 
reorganization of the actin cytoskeleton was observed. The stress fibres present in vehicle 
treated UM-UC-3 carcinoma cells were absent in A83-01 treated UM-UC-3 carcinoma 
cells. Cortical actin was observed in A83-01 treated cells, suggesting a switch to a more 
epithelial phenotype.    
